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EASL–EORTC Clinical Practice Guidelines (CPG) on the manage-
ment of hepatocellular carcinoma (HCC) deﬁne the use of surveil-
lance, diagnosis, and therapeutic strategies recommended for
patients with this type of cancer. This is the ﬁrst European joint
effort by the European Association for the Study of the Liver
(EASL) and the European Organization for Research and Treat-
ment of Cancer (EORTC) to provide common guidelines for the
management of hepatocellular carcinoma. These guidelines
update the recommendations reported by the EASL panel of
experts in HCC published in 2001 [1]. Several clinical and scien-
tiﬁc advances have occurred during the past decade and, thus, a
modern version of the document is urgently needed.
The purpose of this document is to assist physicians, patients,
health-care providers, and health-policy makers from Europe and
worldwide in the decision-making process according to evidence-
based data. Users of these guidelines should be aware that the
recommendations are intended to guide clinical practice in cir-
cumstances where all possible resources and therapies are avail-
able. Thus, they should adapt the recommendations to their local
regulations and/or team capacities, infrastructure, and cost–
beneﬁt strategies. Finally, this document sets out some recom-
mendations that should be instrumental in advancing the
research and knowledge of this disease and ultimately contribute
to improve patient care.
The EASL–EORTC CPG on the management of hepatocellular
carcinoma provide recommendations based on the level of evi-Journal of Hepatology 20
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These Guidelines were developed by the EASL and the EORTC and are published
simultaneously in the Journal of Hepatology (volume 56, issue 4) and the European
Journal of Cancer (volume 48, issue 5).dence and the strength of the data (the classiﬁcation of evidence
is adapted from National Cancer Institute [2]) (Table 1A) and the
strength of recommendations following previously reported sys-
tems (GRADE systems) (Table 1B).Clinical Practice Summary
The clinical practice guidelines below will give advice for up to
date management of patients with HCC as well as providing an
in-depth review of all the relevant data leading to the conclusions.
Clinical Practice Summary
Surveillance 
• Patients at high risk for developing HCC should be entered into 
surveillance programs. Groups at high risk are depicted in Table 
3  
(evidence 1B/3A; recommendation 1A/B)
• Surveillance should be performed by experienced personnel 
in all at-risk populations using abdominal ultrasound every 6 
months
(evidence 2D; recommendation 1B)
Exceptions: A shorter follow-up interval (every 3-4 
months) is recommended in the following cases: (1). 
Where a nodule of less than 1 cm has been detected 
(see recall policy), (2). In the follow-up strategy after 
resection or loco-regional therapies 
(evidence 3D; recommendation 2B)
• Patients on the waiting list for liver transplantation should 
be screened for HCC in order to detect and manage tumor 
progression and to help define priority policies for transplantation 
(evidence 3D; recommendation 1B)
Recall policy
• In cirrhotic patients, nodules less than 1 cm in diameter detected 
by ultrasound should be followed every 4 months the first year 
and with regular checking every 6 months thereafter
(evidence 3D; recommendation 2B)
• In cirrhotic patients, diagnosis of HCC for nodules of 1-2 
cm in diameter should be based on non-invasive criteria or 
biopsy-proven pathological confirmation. In the latter case, 
it is recommended that biopsies are assessed by an expert 
hepatopathologist. A second biopsy is recommended in case 
of inconclusive findings, or growth or change in enhancement 
pattern identified during follow-up
(evidence 2D; recommendation 1B)
• In cirrhotic patients, nodules more than 2 cm in diameter can be 
diagnosed for HCC based on typical features on one imaging 
technique. In case of uncertainty or atypical radiological findings, 
diagnosis should be confirmed by biopsy 
(evidence 2D; recommendation 1A)12 vol. 56 j 908–943
Clinical Practice Summary
Diagnosis
• Diagnosis of HCC is based on non-invasive criteria or pathology 
(evidence 2D; recommendation 1A)
• Pathological diagnosis of HCC is based on the recommendations 
of the International Consensus Panel. Immunostaining for GPC3, 
HSP70, and glutamine synthetase and/or gene expression  
(GPC3, LYVE1 and survivin) are recommended to differentiate high 
grade dysplastic nodules from early HCC 
(evidence 2D; recommendation 2B)
Additional staining can be considered to detect progenitor cell 
features (K19 and EpCAM) or assess neovascularisation (CD34)
• Non-invasive criteria can only be applied to cirrhotic patients and are 
based on imaging techniques obtained by 4-phase multidetector CT 
scan or dynamic contrast-enhanced MRI. Diagnosis should be based 
on the  of the typical hallmark of HCC (hypervascular 
in the arterial phase with washout in the portal venous or delayed 
phases). While one imaging technique is required for nodules 
beyond 1 cm in diameter (evidence 2D; recommendation 2B), a 
more conservative approach with 2 techniques is recommended 
in suboptimal settings. The role of contrast-enhanced ultrasound 
(CEUS) and angiography is controversial. PET-scan is not accurate 
for early diagnosis
Staging systems
• Staging systems in HCC should  outcome prediction and 
treatment assignment. They should facilitate exchange of information, 
prognosis prediction and trial design. Due to the nature of HCC, 
the main prognostic variables are tumor stage, liver function and 
performance status
• The BCLC staging system is recommended for prognostic prediction 
and treatment allocation
(evidence 2A; recommendation 1B)
This staging system can be applied to most HCC patients, as 
long as  considerations for special subpopulations (liver 
transplantation) are incorporated
• Other staging systems applied alone or in combination with BCLC are 
not recommended in clinical practice
• Molecular  of HCC based on gene signatures or 
molecular abnormalities is not ready for clinical application 
(evidence 2A; recommendation  1B)
Treatment
• Treatment allocation is based on the BCLC allocation system
Resection
• Resection is the  treatment option for patients with solitary 
tumors and very well-preserved liver function,  as normal 
bilirubin with either hepatic venous pressure gradient ≤10 mmHg or 
platelet count ≥100,000
(evidence 2A; recommendation 1B)
Anatomical resections are recommended
(evidence 3A; recommendation 2C)
• Additional indications for patients with multifocal tumors meeting 
Milan criteria (≤3 nodules ≤3 cm) or with mild portal hypertension not 
suitable for liver transplantation require prospective comparisons with 
loco-regional treatments
(evidence 3A; recommendation 2C) 
• Peri-operative mortality of liver resection in cirrhotic patients is 
expected to be 2-3%
• Neo-adjuvant or adjuvant therapies have not proven to improve 
outcome of patients treated with resection (or local ablation) 
(evidence 1D; recommendation 2C)
• Tumor recurrence represents the major complication of resection and 
the pattern of recurrence  subsequent therapy allocation 
and outcome. In case of recurrence, the patient will be re-assessed 
by BCLC staging, and re-treated accordingly
Liver Transplantation
• Liver transplantation is considered to be the  treatment option
for patients with single tumors less than 5 cm or ≤3 nodules ≤3 cm
(Milan criteria) not suitable for resection
(evidence 2A; recommendation 1A)
• Peri-operative mortality and one-year mortality are expected to be 
approximately 3% and ≤10%, respectively
• Extension of tumor limit criteria for liver transplantation for HCC has 
not been established. Modest expansion of Milan criteria applying 
the “up-to-seven” in patients without microvascular invasion achieves 
competitive outcomes, and thus this indication requires prospective 
validation
(evidence 2B; recommendation 2B)
• Neo-adjuvant treatment can be considered for loco-regional therapies 
if the waiting list exceeds 6 months due to good cost-effectiveness 
data and tumor response rates, even though impact on long-term 
outcome is uncertain
(evidence 2D; recommendation 2B)
• Down-staging policies for HCCs exceeding conventional criteria 
cannot be recommended and should be explored in the context 
of prospective studies aimed at survival and disease progression 
end-points 
(evidence 2D; recommendation 2C)
Assessment of downstaging should follow  RECIST criteria
• Living donor liver transplantation is an alternative option in patients 
with a waiting list exceeding 6-7 months, and offers a suitable setting 
to explore extended indications within research programs
(evidence 2A; recommendation 2B) 
Local ablation
• Local ablation with radiofrequency or percutaneous ethanol injection 
is considered the standard of care for patients with BCLC 0-A tumors 
not suitable for surgery 
(evidence 2A; recommendation 1B) 
Other ablative therapies, such as microwave or cryoablation, are still 
under investigation 
• Radiofrequency ablation is recommended in most instances as the 
main ablative therapy in tumors less than 5 cm due to a significantly
better control of the disease
(evidence 1iD; recommendation 1A) 
Ethanol injection is recommended in cases where radiofrequency 
ablation is not technically feasible (around 10-15%)
• In tumors <2 cm, BCLC 0, both techniques achieve complete 
responses in more than 90% of cases with good long-term outcome. 
Whether they can be considered as competitive alternatives to 
resection is uncertain
(evidence 1iA; recommendation 1C)
Chemoembolization and transcatheter therapies
• Chemoembolization is recommended for patients with BCLC stage 
B, multinodular asymptomatic tumors without vascular invasion or 
extra-hepatic spread 
(evidence 1iiA; recommendation 1A)
The use of drug-eluting beads has shown similar response rates 
than gelfoam-lipiodol particles associated with less systemic adverse 
events
(evidence 1D; recommendation 2B)
Chemoembolization is discouraged in patients with decompensated 
liver disease, advanced liver dysfunction, macroscopic invasion or 
extrahepatic spread
(evidence 1iiA; recommendation 1B)
Bland embolization is not recommended
• Internal radiation with 131I or 90Y glass beads has shown promising 
anti-tumoral results with a safe  but cannot be recommended
as standard therapy. Further research trials are needed to establish a 
competitive  role in this population 
(evidence 2A; recommendation 2B)
• Selective intra-arterial chemotherapy or lipiodolization are not 
recommended for the management of HCC 
(evidence 2A; recommendation 2B) 
• External three-dimensional conformal radiotherapy is under 
investigation, and there is no evidence to support this therapeutic 
approach in the management of HCC
(evidence 3A; recommendation 2C)
modified
efficacy
profile,
first-line
profiles
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Systemic therapies
• Sorafenib is the standard systemic therapy for HCC. It is indicated 
for patients with well-preserved liver function (Child-Pugh A class) 
and with advanced tumors (BCLC C) or those tumors progressing 
upon loco-regional therapies
(evidence 1iA; recommendation 1A) 
• There are no clinical or molecular biomarkers available to identify 
the best responders to sorafenib
(evidence 1A; recommendation 2A)
• Systemic chemotherapy, tamoxifen, immunotherapy, anti-
androgen, and herbal drugs are not recommended for the clinical 
management of HCC patients
(evidence 1-2A; recommendation 1A/B)
• There is no available second-line treatment for patients with 
intolerance or failure to sorafenib. Best supportive care or the 
inclusion of patients in clinical trials is recommended in this setting 
(recommendation 2B)
• In  circumstances, radiotherapy can be used to alleviate
pain in patients with bone metastasis
(evidence 3A; recommendation 2C) 
• Patients at BCLC D stage should receive palliative support 
including management of pain, nutrition and psychological support. 
In general, they should not be considered for participating in clinical 
trials (recommendation 2B)
specific
Table 1A. Levels of evidence according to study design and end-points
National Cancer Institute: PDQ Levels of Evidence for Adult and Pediatric
Cancer Treatment Studies. Bethesda [2]–.
Strength of evidence according to study design: 
Level 1:  Randomized controlled clinical trials or meta- 
analyses of randomized studies*
(i) Double-blinded 
(ii) Non-blinded treatment delivery
Level 2:  Non-randomized controlled clinical trials** 
Level 3: Case series*** 
(i) Population-based, consecutive series 
(ii) Consecutive cases (not population-based)
(iii) Non-consecutive cases
Strength of evidence according to end-points:
C. Carefully assessed quality of life
D. Indirect surrogates#
(i) Event-free survival
(ii) Disease-free survival
(iii) Progression-free survival
(iv) Tumor response rate
A. Total mortality (or overall survival from a defined time)
B. Cause-specific mortality (or cause-specific mortality from a
defined time)
–National Cancer Institute: PDQ Levels of Evidence for Adult and Paediatric
Cancer Treatment Studies. Bethesda, MD: National Cancer Institute. Date last
modiﬁed 26/August/2010. Available at: http://cancer.gov/cancertopics/pdq/lev-
els-evidence-adult-treatment/HealthProfessional. Accessed <March 1st, 2011>.
⁄The randomized, double-blinded controlled clinical trial (1i) is the gold standard
of study design. Meta-analyses of randomized studies are placed in the same
category of strength of evidence as are randomized studies.
⁄⁄This category includes trials in which treatment allocation was made by birth
date, chart number (so-called quasi randomized studies) or subset analyses of
randomized studies (or randomized phase II studies).
⁄⁄⁄All other prospective (cohort studies) or retrospective studies (case–control
studies, case series).
#These end-points may be subjected to investigator interpretation. More
importantly, they may, but do not automatically, translate into direct patient
beneﬁt such as survival or quality of life. Nevertheless, it is rational in many
circumstances to use a treatment that improves these surrogate end-points while
awaiting a more deﬁnitive end-point to support its use.
Clinical Practice GuidelinesEpidemiology, risk factors, and prevention
• The incidence of HCC is increasing in Europe and 
worldwide.
• Vaccination against hepatitis B is recommended to all 
newborns and high risk groups
(evidence: 2D; recommendation 1A)
 
• Governmental health agencies should recommend 
policies for preventing HCV/HBV transmissions, 
encourage life styles preventing obesity and alcohol 
abuse (evidence 3A; recommendation 1A) and 
controlling metabolic conditions, such as diabetes 
(evidence 3; recommendation 2B)
• In patients with chronic hepatitis, antiviral therapies 
leading to maintained HBV suppression in chronic 
hepatitis B and sustained viral response in hepatitis 
C are recommended since they have been shown 
to prevent progression to cirrhosis, and hence HCC 
development (evidence 1A; recommendation 1A). The 
application of antiviral therapies should follow the EASL 
guidelines for management of chronic hepatitis B and C 
infection
• 
therapy in preventing HCC development are not robustly 
demonstrated
(evidence 1D; recommendation 2B)
Once cirrhosis is established, the benefits of anti-viralEpidemiology
The burden of cancer is increasing worldwide. Each year there are
10.9 million new cases of cancer and 6.7 million cancer-related910 Journal of Hepatology 201deaths. The most commonly diagnosed cancers are lung, breast,
and colorectal while the most common causes of cancer death
are lung, stomach, and liver [3,4]. Liver cancer is the sixth most
common cancer (749,000 new cases), the third cause of cancer-
related death (692,000 cases), and accounts for 7% of all cancers
[4]. HCC represents more than 90% of primary liver cancers and
is a major global health problem.
The incidence of HCC increases progressively with advancing
age in all populations, reaching a peak at 70 years [5]. In Chinese
and in black African populations, the mean age of patients with
the tumor is appreciably younger. This is in sharp contrast to
Japan, where the incidence of HCC is highest in the cohort of
men aged 70–79 years [6]. HCC has a strong male preponderance
with a male to female ratio estimated to be 2.4 [4].
The pattern of HCC occurrence has a clear geographical distri-
bution, with the highest incidence rates in East Asia, sub-Saharan
Africa, and Melanesia, where around 85% of cases occur [3,4]. In
developed regions, the incidence is low with the exception of
Southern Europe where the incidence in men (10.5 age-standardized2 vol. 56 j 908–943
Nation M F
Albania 5.8 2.9
Austria 9.3 2.9
Belgium 3.3 1.5
Bosnia-Erzegovina 4.3 1.5
Bulgaria 5.6 2.2
Croatia 7.7 2.4
Czech Republic 5.9 2.4
Denmark 4.0 1.3
Estonia 3.5 1.5
Finland 5.8 2.4
France 10.5 2.2
Germany 6.2 2.2
Great Britain 3.8 1.7
Greece 5.2 2.0
Netherland 2.0 0.8
Hungary 7.5 2.0
Ireland 3.4 1.5
Italy 13.4 4.4
Latvia 4.6 1.8
Lithuania 4.1 1.4
Luxembourg 9.8 3.8
Macedonia 5.3 2.3
Moldova 14.2 4.6
Montenegro 5.3 2.5
Norway 2.2 1.0
Poland 3.1 1.5
Portugal 3.5 1.2
Romania 8.1 3.0
Russia 4.4 1.9
Serbia 4.8 2.6
Slovenia 5.4 1.8
Spain 9.6 2.5
Sweden 3.2 1.4
Switzerland 7.8 2.3
Ukraine 3.2 1.6
Fig. 1. Incidence rates of primary liver cancer according to geographical distribution in Europe. Age-adjusted incidence rates per 100,000 of liver cancer in Europe in
2008. The color intensity is proportional to the magnitude of incidence. M, males; F, females. (Data from: Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM.
GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010.
Available from: http://globocan.iarc.fr.)
Table 1B. Grading evidence and recommendations (adapted from GRADE system).
Grading of evidence Notes Symbol
High quality A
Moderate quality
of effect and may change the estimate
B
Low or very low quality
estimate of effect and is likely to change the estimate. Any estimate of effect is 
uncertain
C
Grading recommendation Notes Symbol
Strong recommendation warranted
evidence, presumed patient-important outcomes, and cost
1
Weaker recommendation Variability in preferences and values, or more uncertainty: more likely a weak 
recommendation is warranted
Recommendation is made with less certainty: higher cost or resource consumption
2
Further research is very unlikely to change our confidence in the estimate of effect
Further research is likely to have an important impact on our confidence in the estimate
Further research is very likely to have an important impact on our confidence in the
Factors influencing the strength of the recommendation included the quality of the
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incidence rates per 100,000) is signiﬁcantly higher than in other
developed regions [7] (Fig. 1).
There is a growing incidence of HCC worldwide. Overall, the
incidence and mortality rates were of 65,000 and 60,240 cases
in Europe and 21,000 and 18,400 cases in the United States in
2008, respectively. It is estimated that by 2020 the number of
cases will reach 78,000 and 27,000, respectively [4]. People
infected with HCV in Europe during the period 1940–60 and in
the United States of America (USA) one decade later led to the
current increase of HCC incidence. In Europe, the incidence and
mortality rates reported are heterogeneous. HCC mortality during
the last decades increased in males in most of the countries (i.e.
Austria, Denmark, Germany, Greece, Ireland, Portugal, Norway,
Spain, Switzerland, and United Kingdom), but decreased in others
(Finland, France, Italy, Netherlands, and Sweden) [7]. In the Uni-
ted States, the rate of HCC deaths appears to have increased by
about 40% over the period 1990–2004, whereas the overall rate
of cancer deaths has declined by about 18% during this same per-
iod [8]. Besides the emergence of liver disease due to hepatitis C,
this growth in incidence may be also due to an increase in HBV-
related HCC, particularly among immigrants from endemic coun-
tries. Conversely, in Japan, a country where the impact of HCV-
related HCC was ﬁrst noticed after World War II, there has been
an apparent decline in the incidence of this neoplasm for the ﬁrst
time since 1990 [6]. Finally, the impact of universal infant vacci-
nation against HBV has decreased the rate of HBV-related HCC in
endemic countries. So far, this has been observed among children
in Taiwan, but it is expected to become more apparent as these
vaccinated children grow into adults [9].
Etiology and risk factors
Approximately 90% of HCCs are associated with a known under-
lying risk factor (Table 2). The most frequent factors include
chronic viral hepatitis (types B and C), alcohol intake and aﬂa-
toxin exposure. In Africa and East Asia, the largest attributableTable 2. Geographical distribution of main risk factors for HCC worldwide.⁄
Geographic area AAIR Risk factors Alcohol Others
M/F HCV
(%)
HBV
(%)
(%) (%)
Europe 6.7/2.3 60-70 10-15 20 10
Southern 10.5/3.3
Northern 4.1/1.8
North America 6.8/2.3 50-60 20 20 10
(NASH)
Asia and Africa 20 70 10 10 
Asia 21.6/8.2
China 23/9.6
Japan  20.5/7.8 70 10-20 10 10
Africa 1.6/5.3
WORLD 16/6 31 54 15
(Aflatoxin)
⁄Updated from Llovet et al. [99], according to IARC data [4]. AAIR, age-adjusted
incidence rate.
912 Journal of Hepatology 201fraction is due to hepatitis B (60%) whereas in the developed
Western world, only 20% of cases can be attributed to HBV infec-
tion, while chronic hepatitis C appears to be the major risk factor
[3]. Worldwide, approximately 54% of cases can be attributed to
HBV infection (which affects 400 million people globally) while
31% can be attributed to HCV infection (which affects 170 million
people), leaving approximately 15% associated with other causes.
Cirrhosis is an important risk factor for HCC, and may be
caused by chronic viral hepatitis, alcohol, inherited metabolic dis-
eases such as hemochromatosis or alpha-1-antitrypsin deﬁ-
ciency, and non-alcoholic fatty liver disease. All etiologic forms
of cirrhosis may be complicated by tumor formation, but the risk
is higher in patients with hepatitis infection. Overall, one-third of
cirrhotic patients will develop HCC during their lifetime [10].
Long-term follow-up studies have demonstrated that approxi-
mately 1–8% per year of patients with cirrhosis develop HCC
(e.g. 2% in HBV-infected cirrhotic patients and 3–8% in HCV-
infected cirrhotic patients) [11]. In general, features of liver dis-
ease severity (low platelet count of less than 100  103, presence
of esophageal varices), in addition to older age and male gender,
correlate with HCC development among patients with cirrhosis
[12]. Recent studies have shown that liver cancer incidence
increases in parallel to portal pressure as directly measured
[13] or in parallel to the degree of liver stiffness as measured
by transient elastography [14,15].
Several studies have identiﬁed HBV-related factors as key pre-
dictors of HCC development in patients with chronic hepatitis B
infection [16]. Hepatitis B virus e antigen (HBeAg) seropositivity
[17], high viral load [18], and genotype C [19] are independent
predictors of HCC development. In addition, hepatitis B viral load
correlates with the risk of progression to cirrhosis [20]. Similarly,
in a recent meta-analysis, HCV genotype 1b is claimed to increase
the risk of HCC development [21].
Dietary exposure to aﬂatoxin B1, derived from the fungi Asper-
gillus ﬂavus and A. parasiticus, is an important co-factor for HCC
development in some parts of Africa and Asia. These molds are
ubiquitous in nature and contaminate a number of staple food-
stuffs in tropical and subtropical regions. Epidemiologic studies
have shown a strong correlation between the dietary intake of
aﬂatoxin B1, TP53 mutations and incidence of HCC, speciﬁcally
in HBV-infected individuals [22]. Regarding other risk factors,
patients with hemochromatosis develop HCC in up to 45% of
cases [23], most often with a background of cirrhosis, and HCC
is well documented as a complication of cirrhosis associated with
alpha-1-antitrypsin deﬁciency [24]. HCC develops occasionally in
patients with Wilson’s disease, but only in the presence of cirrho-
sis [25].
Obesity, diabetes and fatty liver disease have come to be rec-
ognized as a cause of HCC [26,27], although the mechanisms by
which these overlapping conditions contribute to cancer develop-
ment remain elusive. Cirrhosis due to non-alcoholic steatohepati-
tis may give rise to HCC but it appears that these factors may also
be additive to chronic viral hepatitis [27]. Epidemiologic evidence
of a link between cigarette smoking and the occurrence of HCC
was traditionally conﬂicting [26], but recent evidence support
that smoking is a clear co-factor [28]. Heavy smokers have a
higher risk than non-smokers. In the general population, the inci-
dence of HCC is increased among patients with HIV infection
compared to controls, and HIV appears to be an additive co-fac-
tor, exacerbating the risk of HCC in patients with chronic viral
hepatitis [29].2 vol. 56 j 908–943
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Identiﬁcation of mutations in germline DNA that deﬁne
patients at high risk of developing cancer has become a chal-
lenge for surveillance programs and chemopreventive strategies.
This is the case of mutations in BRCA1 or BRCA2 and increased
risk of breast or ovarian cancer [30] or in genes involved in
DNA mismatch repair and hereditary colon cancer [31]. In
HCC, a recent case–control study found a signiﬁcant association
between an epidermal growth factor (EGF) gene polymorphism
and the risk of HCC [32], while another study suggests genetic
predisposition of SNPs at loci involved in immune response
[33]. These ﬁndings require validation by independent
investigators.Prevention
Primary prevention of HCC can be achieved with universal
vaccination against HBV infection [9]. Vaccination against
hepatitis B is recommended to all newborns and high risk
groups, following the recommendations of the World Health
Organization [34]. Since perinatal or early postnatal transmis-
sion is an important cause of chronic HBV infections globally,
the ﬁrst dose of hepatitis B vaccine should be given as soon
as possible after birth, even in low-endemicity countries
(those with prevalence of HBsAg carriers <2%). Vaccination
is also recommended in age-speciﬁc cohorts (young adoles-
cents) and people with risk factors for acquiring HBV infection
(i.e. health workers, travellers to areas where HBV-infection is
prevalent, injecting drug users, and people with multiple sex
partners).
Antiviral treatment for patients with chronic hepatitis B and
C infection should follow the recommendations from existing
EASL guidelines [35,36]. Interferon, lamivudine, adefovir, ente-
cavir, telbivudine and tenofovir are now available for HBV
treatment, but long-term follow-up data assessing their effect
in secondary prevention are only available with interferon
and lamivudine. Observational studies assessing the effect of
interferon showed a potential effect in reduction of HCC inci-
dence [37], but this was not conﬁrmed by Asian case-
controlled studies [38]. Similarly, a randomized controlled trial
(RCT) assessing the effect of lamivudine showed a signiﬁcant
reduction in HCC incidence. Nonetheless, there are some con-
cerns regarding the effects obtained in this study as prevention
of HCC occurrence was not the primary end-point of the study,
and because the marginal effect obtained disappeared once
adjusted for co-variables [39]. As a result, it appears prudent
to conclude that surveillance for HCC should be maintained
in those patients who already qualiﬁed before starting the
treatment.
In hepatitis C viral infection, the results of a meta-analysis of
retrospective studies suggest that the risk of HCC is reduced
among patients with HCV who achieve a sustained virological
response (SVR) with antiviral therapy with interferon–ribavirin
[40]. Once cirrhosis is established, there is no conclusive evidence
that anti-viral therapy can prevent or delay the occurrence of
HCC [41,42]. Maintenance therapy with PEG–interferon in cir-
rhotic patients has not signiﬁcantly decreased the incidence of
HCC according to the HALT-C [43,44] and EPIC studies [45]. Addi-
tional studies are required to test the potential preventive effect
of combination with new protease inhibitors (boceprevir, telapre-
vir) in cirrhotic patients.Journal of Hepatology 201Surveillance
• Implementation of surveillance programs to identify 
biomarkers for early HCC detection are a major public 
health goal to decrease HCC-related deaths 
(evidence 1D; recommendation 1B)
Government health policy and research agencies should 
address these needs
• Patients at high risk for developing HCC should be 
entered into surveillance programs. Groups at high risk 
are depicted in Table 3 
(evidence 1B/3A; recommendation 1A/B) 
• Surveillance should be performed by experienced 
personnel in all at-risk populations using abdominal 
ultrasound every 6 months 
(evidence 2D; recommendation 1B) 
Exceptions: A shorter follow-up interval (every 3-4 
months) is recommended in the following cases: 
1. Where a nodule of less than 1 cm has been 
detected (see recall policy), 2. In the follow-up 
strategy after resection or loco-regional therapies 
(evidence 3D; recommendation 2B)
• Accurate tumor biomarkers for early detection need to 
be developed. Data available with tested biomarkers 
(i.e. AFP, AFP-L3 and DCP) show that these tests are 
suboptimal for routine clinical practice 
(evidence 2D; recommendation 2B) 
• Patients on the waiting list for liver transplantation should 
be screened for HCC in order to detect and manage 
transplantation  
(evidence 3D; recommendation 1B)
at-risk candidate populations and identification of
tumor progression and to help define priority policies forSurveillance consists of the periodic application of a diagnos-
tic test to subjects at risk for developing a given disease. Its use-
fulness and applicability are inﬂuenced by several factors, such as
the incidence of the surveyed disease in the target population, the
availability of efﬁcient diagnostic test(s) at bearable costs and
their acceptability by the target population, and the availability
of treatments and their effectiveness [46]. The aim of surveillance
is to obtain a reduction in disease-related mortality. This is usu-
ally achieved through an early diagnosis (stage migration) that, in
turn, enhances the applicability and cost–effectiveness of cura-
tive therapies. Stage migration, however, cannot serve as a surro-
gate for the main end-point, which is patient survival.
HCC is a condition which lends itself to surveillance as at-risk
individuals can readily be identiﬁed because of the presence of
underlying viral hepatitis or other liver diseases. In fact, in the
Western world, HCC arises in a cirrhotic background in up to 90%
of cases [47], and cirrhosis itself is a progressive disease that affects
patient survival. The presence of cirrhosis then inﬂuences the
chances for anti-tumoral treatment and affects their results, thus
rendering early diagnosis of HCC even more crucial. Moreover,
many available treatments can have an adverse impact on cirrho-2 vol. 56 j 908–943 913
Table 3. Recommendations for HCC surveillance: categories of adult patients
in whom surveillance is recommended.
1. Cirrhotic patients, Child-Pugh stage A and B* 
2. Cirrhotic patients, Child-Pugh stage C awaiting 
liver transplantation** 
3. Non-cirrhotic HBV carriers with active hepatitis or family 
history of HCC***
4. Non-cirrhotic patients with chronic hepatitis C and advanced 
liver fibrosis F3****
⁄Evidence 3A; strength B1;
⁄⁄evidence 3D; strength B1;
⁄⁄⁄evidence 1B; strength A1 for Asian patients; evidence 3D; strength C1 for
Western patients;
⁄⁄⁄⁄evidence 3D; strength B1 for Asian patients; evidence 3D; strength B2 for
Western patients.
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sis, and the exact cause of death, which could be either the under-
lying disease or HCC, cannot be clearly deﬁned in some instances.
For this reason, a reduction in overall mortality represents a more
appropriate end-point to assess the efﬁcacy of surveillance.
Target populations
Cirrhotic patients
Decision analysis and cost–effectiveness models suggest that an
intervention is considered cost-effective if it provides gains of life
expectancy of at least 3 months with a cost lower than approxi-
mately US$ 50,000 per year of life saved [48]. Cost–effectiveness
studies indicate that an incidence of 1.5%/year or greater would
warrant surveillance of HCC in cirrhotic patients [49], irrespective
of its etiology [10,17,50,51]. It may also be possible to identify
cirrhotic patients at low risk of developing HCC [52–54] and
hence exclude them from surveillance, thereby saving costs
although this approach is not proven yet. Conversely, the pres-
ence of advanced cirrhosis (Child–Pugh class C) prevents poten-
tially curative therapies from being employed, and thus
surveillance is not cost-effective in these patients [1,55]. As an
exception, patients on the waiting list for liver transplantation,
regardless of the liver functional status, should be screened for
HCC in order to detect tumors exceeding conventional criteria
and to help deﬁne priority policies for transplantation. Finally,
although it seems intuitive that surveillance might not be cost-
effective above a certain age cut-off, the lack of data prevents
the adoption of any speciﬁc recommendation.
Non-cirrhotic subjects
Patients with chronic HBV infection are at risk of HCC develop-
ment even in the absence of cirrhosis. In these cases, the recom-
mended cut-off of annual incidence above which surveillance
should be recommended cannot be applied. The cut-off of annual
incidence in these patients is ill-deﬁned, albeit expert opinion
indicates that it would be warranted if HCC incidence is at least
0.2%/year [56,57]. Thus, cost–beneﬁt modeling is needed in this
scenario. The incidence of HCC in adult Asian or African active
HBV carriers or with a family history of HCC exceeds this value,
whereas HCC incidence ranges from 0.1% to 0.4%/year in Western
patients with chronic HBV infection [58,59]. Viral load also
appears to increase the risk of developing HCC. In Asian patients,
serum HBV-DNA above 10,000 copies/ml was associated with an
annual risk above 0.2%/year [18].
Unfortunately, there is scanty and sometimes contradictory
information on the incidence of HCC in patients with chronic hepa-
titis C without cirrhosis. Data from Japan would suggest that
patients with mild ﬁbrosis have a yearly HCC incidence of 0.5%
[51]. A recent study from the United States has pointed out that
HCC does occur in patients with chronic hepatitis C and bridging
ﬁbrosis in the absence of cirrhosis (Metavir F3) [12]. The fact that
the transition from advanced ﬁbrosis and cirrhosis cannot be accu-
rately deﬁned led the EASL guidelines to recommend surveillance
also for patients with bridging ﬁbrosis [1]. This panel also endorses
such a policy. In this respect, transient elastography appears to be a
promising tool able to stratify patients at differentHCC risks [14,60].
Information about the incidence of HCC in patients with non-
viral chronic liver disease without cirrhosis, such as non-alcoholic
and alcoholic steatohepatitis, autoimmune liver disease, genetic
hemochromatosis, a1-antitripsin deﬁciency, and Wilson disease914 Journal of Hepatology 201is limited [23–25,61]. However, available evidence suggests that
HCC usually arises in these contexts once cirrhosis is established
[1]. Certainly, patients with metabolic syndrome or non-alcoholic
steatohepatitis leading to cirrhosis should undergo surveillance
[62], whereas the risk of HCC development is not established in
non-cirrhotic individuals.
Treated viral chronic hepatitis
Recent advances in therapy have led to relatively high rates of viral
clearance or suppression among those patients being treated for
chronic hepatitis B or C. Successful treatment, leading to sustained
virological response in chronic hepatitis C, and HBeAg seroconver-
sion or sustained HBV-DNA suppression in chronic hepatitis B,
decreases, but does not eliminate the risk of HCC [63–66]. Surveil-
lance should be offered to treated patientswith chronic hepatitis B
who remain at risk of HCC development due to baseline factors, or
to those with HCV-induced advanced ﬁbrosis or cirrhosis, even
after achieving sustained virological response.Surveillance tests
Tests that can be used in HCC surveillance include serological and
imaging examinations. The imaging test most widely used for
surveillance is ultrasonography (US). US has an acceptable diag-
nostic accuracy when used as a surveillance test (sensitivity rang-
ing from 58% to 89%; speciﬁcity greater than 90%) [67,68]. A
recent meta-analysis including 19 studies has showed that US
surveillance detected the majority of HCC tumors before they
presented clinically, with a pooled sensitivity of 94%. However,
US was less effective for detecting early-stage HCC, with a sensi-
tivity of only 63% [69]. In contrast, in a recent Japanese cohort
including 1432 patients, careful US surveillance performed by
highly skilled operators resulted in an average size of the
detected tumors of 1.6 ± 0.6 cm, with less than 2% of the cases
exceeding 3 cm [70].
The widespread popularity of US also relies on the absence of
risks, non-invasiveness, good acceptance by patients and rela-
tively moderate cost. Nonetheless, US detection of HCC on a cir-
rhotic background is a challenging issue. Liver cirrhosis is2 vol. 56 j 908–943
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characterized by ﬁbrous septa and regenerative nodules. These
features produce a coarse pattern on US, which may impair iden-
tiﬁcation of small tumors. Because of these limitations, the per-
formance of US in early detection of HCC is highly dependent
on the expertise of the operator and the quality of the equipment.
Thus, special training for ultrasonographers is recommended. The
recent introduction of US contrast agents has not proven to
increase the ability of US to detect small HCC tumors [71].
There are no data to support the use of multidetector CT or
dynamicMR imaging for surveillance. Practical experience suggests
that the rate of false-positive results that will trigger further inves-
tigation is very high and non-cost-effective. These circumstances
are overcome in the setting of the waiting list for liver transplanta-
tion where CT scan or MRI are alternatives to US. These techniques
should be also considered when obesity, intestinal gas, and chest
wall deformity prevent an adequate US assessment. Even in these
circumstances, radiation risk due to repeated exposure to CT scan
and high cost of MR make debatable their use in long-term
surveillance.
Serological tests that have been investigated or are under
investigation for early diagnosis of HCC include alpha-fetoprotein
(AFP), des-gamma-carboxy prothrombin (DCP) – also known as
prothrombin induced by Vitamin K Absence II (PIVKA II) – the ratio
of glycosylated AFP (L3 fraction) to total AFP, alpha-fucosidase, and
glypican 3 [12,72]. AFP is the most widely tested biomarker in
HCC. It is known that persistently elevated AFP levels are a risk fac-
tor for HCC development and can be used to help deﬁne at-risk
populations [73]. Of note is that AFP has been mostly tested in
the diagnostic mode rather than for surveillance. This is relevant,
since its performance as a diagnostic test cannot be extrapolated
to the surveillance setting. As a serological test for surveillance,
AFP has a suboptimal performance. One randomized study [74]
and one population-based observational study [75] reached oppo-
site results. The latter study provides rationale for testing AFP in
special populations or health care environments when US is not
readily available [75]. However, when combined with US, AFP lev-
els are only able to provide additional detection in 6–8% of cases
not previously identiﬁed by US. Reasons for the suboptimal perfor-
mance of AFP as a serological test in the surveillance mode are
twofold. Firstly, ﬂuctuating levels of AFP in patients with cirrhosis
might reﬂect ﬂares of HBV or HCV infection, exacerbation of
underlying liver disease or HCC development [76]. Secondly, only
a small proportion of tumors at an early stage (10–20%) present
with abnormal AFP serum levels, a fact that has been recently cor-
related with a molecular subclass of aggressive HCCs (S2 class,
EpCAM positive) [77–79]. When used as a diagnostic test, AFP lev-
els at a value of 20 ng/ml show good sensitivity but low speciﬁcity,
whereas at higher cut-offs of 200 ng/ml the sensitivity drops to
22% with high speciﬁcity [80].
All other serummarkers have usually been evaluated, alone or
in combination, in a diagnostic rather than surveillance setting.
Moreover, their diagnostic performance has often been assessed
at an HCC prevalence remarkably higher than that expected in
the context of surveillance [81]. In the latter setting, DCP, mea-
sured with a ﬁrst generation assay, did not offer substantial
advantages with respect to AFP [82]. In addition, DCP levels have
been associated to portal vein invasion and advanced tumoral
stage, a fact that prevents the usage of this marker for early detec-
tion [82]. A similar situation occurs with AFP-L3 fraction levels
[83]. At present, none of these tests can be recommended to sur-Journal of Hepatology 201vey patients at risk of developing HCC. Several markers, such as
fucosylated proteins, are currently under investigation [84].
In conclusion, US can be seen as the most appropriate test to
perform surveillance. The combination with AFP is not recom-
mended, as the 6–8% gain in the detection rate does not counter-
balance the increase in false positive results, ultimately leading to
an about 80% increase in the cost of each small HCC diagnosed
[69,85].
Surveillance efﬁcacy
Two randomized controlled trials have been published on HCC
surveillance. In one population-based study cluster randomiza-
tion (randomizing entire villages) was performed comparing sur-
veillance (US and AFP measurements every 6 months) versus no
surveillance in a population of Chinese patients with chronic hep-
atitis B infection, regardless of the presence of cirrhosis [86].
Despite suboptimal adherence to the surveillance program
(55%), HCC-related mortality was reduced by 37% in the surveil-
lance arm as a result of increased applicability of resection in
detected cases. The other AFP-based surveillance study carried
out in Qidong (China) in high-risk individuals (males, HBsAg+)
did not identify differences in overall survival [74].
Other types of evidence include population and non-popula-
tion-based cohorts and cost–effectiveness analysis, which mostly
reinforce the beneﬁts of regular US schemes [55,69,87–93]. How-
ever, these studies are heterogeneous as far as stage and etiology
of liver disease, and surveillance protocols. Moreover, almost all
suffer from methodological biases such as lead-time bias (appar-
ent improvement of survival due to an anticipated diagnosis) and
length time bias (over-representation of slower-growing
tumors). While the latter is unavoidable in this type of study,
lead-time bias can be minimized using correction formulas.
When this was done, the advantage of surveillance remained
[94].
Surveillance interval
The ideal interval of surveillance for HCC should be dictated by
two main features: rate of tumor growth up to the limit of its
detectability, and tumor incidence in the target population. Based
on available knowledge on mean HCC volume doubling time [87–
89]; a 6-month interval represents a reasonable choice. Consider-
ing, though, that inter-patient variability is so huge, a shorter 3-
month interval has been proposed by Japanese guidelines
[90,95]. However, the unique randomized study comparing 3 ver-
sus 6-month based programs failed to detect any differences [91].
On the other hand, cohort comparisons of 6 versus 12-month
schemes provide similar results [52,92], while retrospective stud-
ies identiﬁed better performance of the 6-month interval in terms
of stage migration (small HCC amenable for curative treatments)
[96] and survival [97]. Meta-analysis of prospective studies has
shown that the pooled sensitivity of US-based surveillance
decreases from 70% with the 6-month program to 50% with the
annual program [69].
Finally, cost–effectiveness studies have shown that semi-annual
US-based surveillance improves quality-adjusted life expectancy at
a reasonable cost [98]. In light of available knowledge, a 6-month
scheduled surveillance appears the preferable choice. Further trials
in this setting would be difﬁcult to implement.2 vol. 56 j 908–943 915
• Diagnosis of HCC is based on non-invasive criteria or 
pathology 
(evidence 2D; recommendation 1A)  
• Pathological diagnosis of HCC is based on the 
recommendations of the International Consensus Panel. 
Immunostaining for GPC3, HSP70, and glutamine 
GPC3, 
LYVE1 and survivin) are recommended to differentiate 
high grade dysplastic nodules from early HCC  
(evidence 2D; recommendation 2B)  
Additional staining can be considered to detect 
progenitor cell features (K19 and EpCAM) or assess 
neovascularisation (CD34) 
• Non-invasive criteria can only be applied to cirrhotic 
patients and are based on imaging techniques obtained 
by 4-phase multidetector CT scan or dynamic 
contrast-enhanced MRI. Diagnosis should be based 
(hypervascular in the arterial phase with washout in the 
portal venous or delayed phases). While one imaging 
technique is required for nodules beyond 
1 cm in diameter (evidence 2D; recommendation 
2B), a more conservative approach with 2 techniques is 
recommended in suboptimal settings.  
The role of contrast-enhanced ultrasound (CEUS) and 
angiography is controversial. PET-scan is not accurate 
for early diagnosis
synthetase and/or gene expression profiles (
on the identification of the typical hallmark of HCC
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Recall policy
• In cirrhotic patients, nodules less than 1 cm in diameter 
detected by ultrasound should be followed every 
6 months thereafter  
(evidence 3D; recommendation 2B) 
 
• In cirrhotic patients, diagnosis of HCC for nodules of 
1-2 cm in diameter should be based on non-invasive 
In the latter case, it is recommended that biopsies are 
assessed by an expert hepatopathologist. A second 
during follow-up  
(evidence 2D; recommendation 1B)
• In cirrhotic patients, nodules more than 2 cm in diameter 
can be diagnosed for HCC based on typical features on 
one imaging technique. In case of uncertainty or atypical 
biopsy  
(evidence 2D; recommendation 1A)
4 months the first year and with regular checking every
criteria or biopsy-proven pathological confirmation.
biopsy is recommended in case of inconclusive findings,
or growth or change in enhancement pattern identified
radiological findings, diagnosis should be confirmed by
Recall policy is crucial for the success of surveillance proce-
dures. It consists of a deﬁned algorithm to be followed when sur-
veillance tests show an abnormal result. This deﬁnition must take
into account the ideal target of surveillance, i.e. the identiﬁcation
of HCC at a very early stage (2 cm or less), when radical treat-
ments can be applied with the highest probability of long-term
cure [99]. In case of HCC, abnormal US results are either a newly
detected focal lesion or a known hepatic lesion that enlarges and/
or changes its echo pattern [100].
Pathology studies show that themajorityof nodules smaller than
1 cm, that can be detected in a cirrhotic liver, are not HCCs [101].
Thus, a tight follow-up is recommended in these cases (Fig. 2). An
accepted rule is to consider any nodule larger than about 1 cm as
an abnormal screening result warranting further investigation
[56]. These new nodules should trigger the recall strategy for diag-
nosis with non-invasive or invasive (biopsy) criteria, as described
in the section of diagnosis. If a diagnosis cannot be reached with
non-invasive criteria due to atypical radiological appearance, then
biopsy is recommended. If even biopsy provides inconclusive
results, then a tight follow-up every 4 months is recommended.
A second biopsy can be considered in case of growth or change in
the enhancement pattern. Upon detection of a suspicious nodule,
the recommendedpolicy is to evaluate the patient in a referral cen-
ter with appropriate human and technical resources [56].Diagnosis
Nowadays, early HCC diagnosis is feasible in 30–60% of cases
in developed countries and this enables the application of
curative treatments. In fact, while tumors less than 2 cm in diam-
eter represented <5% of the cases in the early nineties in Europe,
currently they represent up to 30% of cases in Japan. This trend is
expected to continue growing in parallel to the wider implemen-916 Journal of Hepatology 201tation of surveillance policies in developed countries [102]. How-
ever, detection of these minute nodules of 2 cm poses a
diagnostic challenge as they are difﬁcult to characterize by radio-
logical or pathological examination [103–105].
Proper deﬁnition of nodules as pre-neoplastic lesions or early
HCC has critical implications. Dysplastic lesions should be fol-
lowed by regular imaging studies, since at least one-third of them
develop a malignant phenotype [106,107]. Conversely, early
tumors are treated with potentially curative procedures – albeit
expensive – such as resection, transplantation and percutaneous
ablation. Thus, there is an urgent need to identify better tools to
characterize these lesions. Otherwise, the cost–effectiveness of
the recall policies applied within surveillance programs will be
signiﬁcantly undermined.
Non-invasive diagnosis
Accurate diagnosis of small liver nodules is of paramount impor-
tance. Until 2000, diagnosis was based on biopsy. This approach
had some limitations related to feasibility due to location and risk
of complications, such as bleeding or needle-track seeding [108].
In addition, achieving accuracy in differentiating between high-
grade dysplastic nodules and early HCCs was complex, since stro-
mal invasion, the most relevant criteria, is difﬁcult to recognize
even for an expert pathologist [105]. In 2001, a panel of experts
on HCC convened in Barcelona by EASL reported for the ﬁrst time
non-invasive criteria for HCC based on a combination of imaging
and laboratory ﬁndings [1]. In principle, a unique dynamic radiolog-
ical behavior (contrast up-take in the arterial phase by CT, MRI,
angiography or US) represented the backbone of radiological diag-
nosis of early HCC. In cirrhotic patients with nodules >2 cm, coinci-2 vol. 56 j 908–943
Mass/Nodule on US
<1 cm
Repeat US at 4 mo
Growing/changing
character
Investigate
according to size
Yes
HCC
Inconclusive
Biopsy HCC Biopsy
No Yes No
Stable
4-phase CT/dynamic
contrast enhanced MRI
1 or 2 positive techniques*:
HCC radiological hallmarks**
1 positive technique:
HCC radiological hallmarks**
4-phase CT or dynamic
contrast enhanced MRI
1-2 cm >2 cm
Fig. 2. Diagnostic algorithm and recall policy. ⁄One imaging technique only recommended in centers of excellence with high-end radiological equipment. ⁄⁄HCC
radiological hallmark: arterial hypervascularity and venous/late phase washout.
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nostic, or alternatively, one imaging techniquealongwithAFP levels
above 400 ng/ml. In all other circumstances biopsy wasmandatory.
In 2005, the EASL panel of experts and the American Association for
the Study of Liver Diseases (AASLD) guidelines adopted a new HCC
radiological hallmark, i.e. contrast uptake in the arterial phase and
washout in the venous/late phase [109]. Non-invasive diagnosis
was established by one imaging technique in nodules above 2 cm
showing the HCC radiological hallmark and two coincidental tech-
niques with nodules of 1–2 cm in diameter (CT, MRI and US-con-
trast). AFP levels were dropped from the diagnostic scheme [109].
Recent updated AASLD guidelines have proposed that one imaging
technique (CT or MRI) showing the HCC radiological hallmark suf-
ﬁces for diagnosing tumors of 1–2 cm in diameter [56].
In order to update the EASL guidelines for non-invasive diag-
nostic criteria of HCC, two questions are posed. First, what data
provides reliable non-invasive diagnostic accuracy for nodules
of 1–2 cm in diameter taking into account that the recommenda-
tions apply to a wide range of expert physicians and radiologists.
And second, what imaging techniques can be used. Regarding the
ﬁrst issue, two prospective studies have shown that using 2
imaging techniques is an approach with high PPV and speciﬁcity
[104,109]. In one study including 89 consecutive cases of nodules
between 0.5 and 2 cm detected within surveillance programs in
cirrhotic patients showed that non-invasive criteria are accurate
for the diagnosis of HCC, with a speciﬁcity of 100% [104]. Unfor-
tunately, such an absolute speciﬁcity had the downside of a low
sensitivity of 30%, meaning that two-thirds of nodules required
pathological conﬁrmation. The other study suggested that the
use of a sequential algorithm would maintain an absolute speci-Journal of Hepatology 201ﬁcity but increase the sensitivity, with signiﬁcant savings in
terms of liver biopsy procedures for nodules of 1–2 cm [110]. A
retrospective study reporting diagnostic accuracies of MRI in
large series of transplanted patients showed an overall false posi-
tive rate exceeding 10% when using one imaging technique [111].
Finally, a recent prospective study, testing the accuracy of imag-
ing techniques in nodules between 1 and 2 cm detected by ultra-
sound, showed false positive diagnosis – mostly due to high
grade dysplastic nodules – above 10% with either 1 or 2 imaging
techniques, with a speciﬁcity of 81% and 85%, respectively [112].
Hence, the non-invasive diagnosis of 1–2 cm lesions remains a
challenging issue, with no unequivocal data in prospective vali-
dation studies. While the panel considers incorporating the 1
technique rule in order to have a consistent approach in the ﬁeld,
a more cautious application of this rule is recommended in sub-
optimal settings, where the technology at disposal or the local
skills are not at the high-end level. In these circumstances, we
recommended to use two coincidental techniques, since the neg-
ative consequences of high rates of false-positive diagnosis offset
the beneﬁt. Additional prospective studies to conﬁrm the accu-
racy of this approach are recommended in order to support a
more strong recommendation at the 1A level.
Regardingwhich imaging techniques shouldbeused, it has tobe
pointed out the fact that the HCC radiological hallmark is based on
the tumor vascular dynamic performance. This limits the usage of
US-contrast – sinceUSmicrobubblesare conﬁned to the intravascu-
lar space – as opposed to iodinated contrast-CT or gadolinium-
based MR imaging, in which standard contrast agents are rapidly
cleared from the blood pool into the extracellular space. A recent
study showed that lesions other than HCC, i.e. cholangiocarcinoma,2 vol. 56 j 908–943 917
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displayedhomogeneous contrastuptakeatUS-contrast followedby
washout, i.e. thevascularpattern assumedto represent thehallmark
of HCC [113]. Thus, latest generation CT and/or MRI following
reported protocols are recommended for non-invasive diagnosis
of HCC [114]. On the other hand, recent advances in the use of per-
fusion CT or MRI with liver-speciﬁc contrast agents have not so far
provided solid data to support their use as alternate criteria.
It is important to point out that the HCC radiological hallmark
only occurs in a small proportion of patients with tiny tumors
(1–2 cm) [103], and thus biopsy or tissue biomarkers will be
required in most instances. Delaying diagnosis beyond 2 cm leads
to increased levels of treatment failure or recurrence, since it is
known that satellites andmicroscopic vascular invasion rise expo-
nentially beyond this size cut-off [101]. Therefore, it is crucial to
provide reliable tools for a ﬁnal diagnosis before the 2 cm cut-off.
Pathological diagnosis
Pathological diagnosis of HCC is based on the deﬁnitions of the
International Consensus Group for Hepatocellular Neoplasia
[115] and is recommended for all nodules occurring in non-cir-
rhotic livers, and for those cases with inconclusive or atypical
imaging appearance in cirrhotic livers. Sensitivity of liver biopsy
depends upon location, size and expertise, and might range
between 70% and 90% for all tumor sizes. Pathological diagnosis
is particularly complex for nodules between 1 and 2 cm [105].
Morphological criteria alone still pose problems for the differen-
tial diagnosis of high-grade dysplastic nodules versus early HCC,
especially because the pathological hallmark of HCC, stromal inva-
sion, can be absent or difﬁcult to identify in biopsy specimens
[105]. In a prospective study, ﬁrst biopsy was reported positive
in 60% of cases for tumors less than 2 cm [104]. Thus, a positive
tumor biopsy is clinically useful to rule in a diagnosis of HCC, but
a negative biopsy does not rule out malignancy. The risk of tumor
seeding after liver biopsy is 2.7% with a median time interval
between biopsy and seeding of 17 months [116].
Tissue markers might provide a more across-the-board stan-
dardized diagnosis of these tumors. Distinct technologies such
as genome-wide DNA microarray, qRT-PCR, proteomic and inmu-
nostaining studies have been used in an attempt to identify
markers of early diagnosis of HCC. Few studies, however, include
a thorough analysis of several markers in a training-validation
scheme and with a sufﬁcient number of samples [78]. A study
conducted in 128 human samples described a 13-gene signature
able to identify HCC lesions with high diagnostic accuracy [117].
Similarly, a three-gene signature (the genes that encode GPC3,
LYVE1, and survivin) has been proposed as an accurate molecular
tool (>80% accuracy) to discriminate between dysplastic nodules
and small HCCs (<2 cm) [118]. The performance of this signature
was externally validated in a different set of samples [118,119].
The diagnostic performance of some markers of early HCC
identiﬁed by genomic studies has been prospectively assessed
by immunohistochemistry, a low-cost technique. By examining
the tissue, the pathologist can select a representative tumor sam-
ple without necrosis or inﬂammation and deﬁne the cell type
expressing protein markers and the speciﬁc pattern. A promising
marker is GPC3, which shows a sensitivity of 68–72% with a spec-
iﬁcity superior to 92% [120,121]. Similarly, combinations of dif-
ferent protein markers – HSP70, GPC3, and GS – in 105
hepatocellular nodules performed acceptably (sensitivity and
speciﬁcity of 72% and 100%, respectively) [120], and were after-918 Journal of Hepatology 201wards validated in two larger series [122,123]. The International
Consensus Group of Hepatocellular Neoplasia has adopted the
recommendation to deﬁne a pathological diagnosis of HCC if at
least two of these markers are positive [115]. Additional staining
can be considered to assess neovascularisation (CD34) or poten-
tial progenitor cell origin (Keratin 19, EpCAM) [101,105,124]. In
particular, keratin 19 (K19), a progenitor cell/biliary marker, at
a cut-off of 5% of positive tumor cells with immunohistochemis-
try, has been shown to correlate with poorest outcome
[105,124,125]. Moreover, K19 recognizes biliary features in
mixed forms of HCC/cholangiocarcinoma, which are not always
detected on hematoxylin–eosin stain.
Assessment of disease extension
Assessment of tumor extension is critical for deﬁning staging and
treatment strategy. Several studies with pathological correlation
have shown that dynamic contrast-enhanced MRI and 4-phase
multidetector CT are the most effective imaging techniques for
detecting tumors smaller than 2 cm. However, underestimation
of 25–30% is expected even with the best state-of-the-art tech-
nology [126,127]. Pre-speciﬁed protocols should deﬁne the
amount and rate of contrast given, the precise individualized tim-
ing of the image acquisition and image reconstruction with min-
imum slice thickness. Lipiodol contrast staining should not be
used. Contrast-enhanced ultrasound is unable to compete with
CT and MRI in terms of accuracy for detection of lesions. Bone
scintigraphy can be used for evaluating bone metastases. PET-
based imaging is not accurate to stage early tumors. Pre-opera-
tive staging prior to liver transplantation should include abdom-
inal dynamic CT or MRI, chest CT and bone scintigraphy.
Staging systems
• 
prediction and treatment assignment. They should 
facilitate exchange of information, prognosis prediction 
and trial design. Due to the nature of HCC, the main 
prognostic variables are tumor stage, liver function and 
performance status  
• The BCLC staging system is recommended for 
prognostic prediction and treatment allocation
(evidence 2A; recommendation 1B). This staging 
system can be applied to most HCC patients, as long as 
transplantation) are incorporated   
• 
tools should further facilitate understanding of outcome 
• Other staging systems applied alone or in combination 
with BCLC are not recommended in clinical practice
• 
signatures or molecular abnormalities is not ready for 
clinical application 
(evidence 2A; recommendation 1B) 
Staging systems in HCC should define outcome
specific considerations for special subpopulations (liver
Refinement of BCLC class C by clinical or biomarker
data and trial stratification
Molecular classification of HCC based on gene2 vol. 56 j 908–943
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Cancer classiﬁcation is intended to establish prognosis and
enable the selection of the adequate treatment for the best candi-
dates. In addition, it helps researchers to exchange information
and design clinical trials with comparable criteria. In patients with
HCC, unlikemost solid tumors, the coexistenceof two life-threaten-
ing conditions such as cancer and cirrhosis complicates prognostic
assessments [99,128]. Thus, staging systems for this cancer should
be designed with data coming from two sources. First, prognostic
variables obtained from studies describing the natural history of
cancer and cirrhosis. Second, treatment-dependent variables
obtained from evidence-based studies providing the rationale for
assigning a given therapy to patients in a given subclass.
Based on data reporting the natural history of the disease, the
main clinical prognostic factors in HCC patients are related to
tumor status (deﬁned by number and size of nodules, presence
of vascular invasion, extrahepatic spread), liver function (deﬁned
by Child–Pugh’s class, bilirubin, albumin, portal hypertension,
ascites) and general health status (deﬁned by ECOG classiﬁcation
and presence of symptoms) [129–133]. Etiology has not been
identiﬁed as an independent prognostic factor.
Tissue and serum biomarkers predicting prognosis have been
less explored in HCC patients. Strict rules for incorporating prog-
nostic or predictive markers into clinical practice have been pub-
lished [134]. According to these rules, acceptable biomarkers
should be obtained from randomized investigations, as is the case
with KRAS status and response to cetuximab in colon cancer.
Only in particularly compelling circumstances can prognostic or
predictive markers tested in cohort studies be adopted in clinical
practice. The panel recommends to incorporate biomarkers for
the management of HCC when the following requirements are
met: (1) demonstrate prognostic prediction in properly powered
randomized studies or in training and validation sets from cohort
studies; (2) demonstrate independent prognostic value in muti-
variate analysis, including known clinico-pathological predictive
variables; and (3) conﬁrmation of results using the same technol-
ogy in an external cohort reported by independent investigators.
None of the biomarkers tested so far fulﬁl these criteria in HCC,
but four just require external validation by independent groups:
gene signatures or biomarkers from the tumor (EpCAM signature,
G3-proliferation subclass, and miR-26a) [77,135,136] and adja-
cent tissue (poor-survival signature) [137]. Regarding serum
markers, AFP levels, VEGF and Ang2 have been shown to have
independent prognostic value in large cohorts of untreated
advanced tumors [138]. The prognostic relevance of high AFP lev-
els has been scarcely reported in controlled investigations [139],
but has been shown to predict risk of drop-out in patients on the
waiting list for liver transplantation (cut-off of 200 ng/ml, or by
increases of >15 ng/ml) [140,141], response to local ablation
[142], response to loco-regional therapies [143] and in the out-
come of advanced tumors (cut-off of 200 ng/ml [138]; 400 ng/
ml [130,144]). The heterogeneity of the above studies prevents
the formulation of a clear recommendation, but it is advised to
test levels >200 and/or >400 ng/ml as prognostic factors of poor
outcome in research investigations.
Several staging systems have been proposed to provide a clin-
ical classiﬁcation of HCC. In oncology, the standard classiﬁcation
of cancer is based on the TNM staging. In HCC, the 7th TNMedition
in accordance with the AJCC [145], which was obtained from the
analysis of a series of patients undergoing resection, has several
limitations [146]. First, pathological information is required to
assess microvascular invasion, which is only available in patientsJournal of Hepatology 201treated by surgery (20%). In addition, it does not capture infor-
mation regarding liver functional status or health status. One-
dimensional systems, such as the Okuda staging and the Child–
Pugh classiﬁcation, albeit popular, serve purposes distinct to class
prediction in HCC patients. Among more comprehensive staging
systems, ﬁve have been broadly tested, three European (the
French classiﬁcation [147], the Cancer of the Liver Italian Program
(CLIP) classiﬁcation [130], and the Barcelona-Clínic Liver Cancer
(BCLC) staging system [148,149]) and two Asian (the Chinese Uni-
versity Prognostic Index (CUPI score) [150] and the Japan Inte-
grated Staging (JIS), which was recently reﬁned including
biomarkers (AFP, DCP AFP-L-3) (bm-JIS) [151]). The CUPI and CLIP
scores largely subclassify patients at advanced stages, with a
small number of effectively treated patients. Overall, few of the
most used systems or scores have been externally validated
(BCLC, CUPI, CLIP, and bm-JIS), only two include the three types
of prognostic variables (BCLC, CUPI) and only one assigns treat-
ment allocation to speciﬁc prognostic subclasses (BCLC).
The current EASL–EORTC GP guidelines endorse the Barce-
lona-Clínic Liver Cancer (BCLC) classiﬁcation for several reasons
[148,149]. It includes prognostic variables related to tumor sta-
tus, liver function and health performance status along with
treatment-dependant variables obtained from cohort studies
and randomized trials. It has been externally validated in differ-
ent clinical settings [152–154]. This is an evolving system that
links tumor stage with treatment strategy in a dynamic manner
enabling the incorporation of novel advancements in the under-
standing of the prognosis or management of HCC. In this regard,
the seminal classiﬁcation reported in 1999 [148] was updated
with the incorporation of stage 0 (very early HCC) and chemo-
embolization for intermediate HCC in 2003 [99], and further
modiﬁed in 2008 to incorporate sorafenib as ﬁrst-line treatment
option in advanced tumors [149]. As discussed below, further
reﬁnements in class stratiﬁcation (for instance to incorporate bio-
markers) or treatment allocation resulting from positive high-end
trials are expected in the following years. The BCLC classiﬁcation
was ﬁrst endorsed by the EASL [1], and thereafter by the AASLD
guidelines for the management of HCC [56].
BCLC classiﬁcation: outcome prediction and treatment allocation
The Barcelona-Clínic Liver Cancer (BCLC) classiﬁcation divides
HCC patients in 5 stages (0, A, B, C and D) according to pre-
established prognostic variables, and allocates therapies
according to treatment-related status (Fig. 3). Thus, it provides
information on both prognostic prediction and treatment alloca-
tion. Prognosis prediction is deﬁned by variables related to tumor
status (size, number, vascular invasion, N1, M1), liver function
(Child–Pugh’s) and health status (ECOG). Treatment allocation
incorporates treatment dependant variables, which have been
shown to inﬂuence therapeutic outcome, such as bilirubin, portal
hypertension or presence of symptoms-ECOG.
Early stages
Very early HCC (BCLC stage 0) is deﬁned as the presence of a single
tumor <2 cm in diameter without vascular invasion/satellites in
patients with good health status (ECOG-0) and well-preserved
liver function (Child–Pugh A class). Nowadays, 5–10% of patients
in the West are diagnosed at this stage while in Japan the ﬁgure is
almost 30% due to the widespread implementation of surveil-
lance programs [155]. From pathological studies, though, two2 vol. 56 j 908–943 919
HCC
Stage 0
Resection Liver transplantation(CLT/LDLT)
Curative treatment (30-40%)
Median OS >60 mo; 5-yr survival: 40-70%
RF/PEI TACE
Target: 20%
OS: 20 mo (45-14)
Target: 40%
OS: 11 mo (6-14)
Target: 10%
OS: <3 mo
Sorafenib Best supportivecare
Stage A-C Stage D
PST 0, Child-Pugh A PST 0-2, Child-Pugh A-B PST >2, Child-Pugh C*
Very early stage (0)
Single <2 cm,
Carcinoma in situ
Portal pressure/bilirubin
Associated diseasesIncreased
Normal No Yes
Single 
Single or 3 nodules ≤3 cm,
PS 0
3 nodules ≤3 cm
Multinodular,
PS 0
Portal invasion,
N1, M1, PS 1-2
Early stage (A) Intermediate stage (B) Advanced stage (C) Terminal stage (D)
Fig. 3. Updated BCLC staging system and treatment strategy, 2011.
Clinical Practice Guidelinessubclasses of tumors have been deﬁned: vaguely nodular type –
size around 12 mm without local invasiveness – and the dis-
tinctly nodular type – mean size 16 mm which might show local
invasiveness. Vaguely nodular types are very well-differentiated
HCCs that contain bile ducts and portal veins, have ill-deﬁned
nodular appearance and, by deﬁnition, do not have invaded struc-
tures. Distinctly nodular type show local metastases surrounding
the nodule in 10% of cases, and microscopic portal invasion in up
to 25% [101,105]. Therefore, some tumors smaller than 2 cm are
prone to locally disseminate, but others behave as carcinoma
in situ and those are deﬁned as Stage 0. Recent data have shown
a 5-year survival in 80–90% of patients with resection and liver
transplantation and in 70% with local ablation [156–159].
Whether patients at very early stage can be offered local ablation
as a ﬁrst line treatment option is a topic of controversy. No RCT
addressing this issue have been reported so far and comparison
of cohort studies suffers from selection bias.
Early HCC (BCLC stage A) is deﬁned in patients presenting sin-
gle tumors >2 cm or 3 nodules <3 cm of diameter, ECOG-0 and
Child–Pugh class A or B. Median survival of patients with early
HCC reaches 50–70% at 5 years after resection, liver transplanta-
tion or local ablation in selected candidates [102,160]. The natu-
ral outcome of these cases is ill-deﬁned due the scarcity of
reported data, but it is estimated to be a median survival of
around 36 months. An improvement in survival is universal when920 Journal of Hepatology 201applying the so-called treatment-dependent variables in the
selection of candidates.
Tumor status is deﬁned by size of the main nodule and multi-
centricity (single 2–5 cm, 3 nodules 63 cm), each of these catego-
ries showing signiﬁcantly different outcomes. As discussed below,
single tumors beyond 5 cm are still considered for surgical resec-
tion as ﬁrst option, because if modern MRI is applied in pre-oper-
ative staging, the fact that solitary large tumors remain single and
with nomacrovascular involvement – whichmight be common in
HBV-related HCC – reﬂects a more benign biological behavior.
Variables related to liver function are relevant for candidates to
resection.Absenceof clinically relevantportalhypertensionandnor-
mal bilirubin are key predictors of survival in patients with single
tumors undergoing resection [161]. Similarly, Child–Pugh class A is
the strongest prognostic variable in patients undergoing local abla-
tion, along with tumor size and response to treatment [162]. Since
liver transplantation may potentially cure both the tumor and the
underlying liver disease, variables mostly related with HCC have
been clearly established as prognostic factors (single tumors
65 cm or 3 nodules 63 cm), deﬁning the so-called Milan criteria.
Intermediate-advanced HCC
Prognosis of HCC was assumed to be poor for unresectable cases,
withamedian survival of less than1year.Analysis of heterogeneous
outcomes within 25 RCT (2 year survival 8–50%) [131,133,139,163]2 vol. 56 j 908–943
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leads to the identiﬁcationof at least three subgroupsofpatientswith
unresectableHCC: the intermediate, advancedandend-stage classes,
according to the BCLC classiﬁcation.
Intermediate HCC (BCLC stage B): Untreated patients at an
intermediate stage – BCLC B class (multinodular asymptomatic
tumors without an invasive pattern) present a median survival
of 16 months [139,164], or 49% at 2 year [133]. Chemoemboliza-
tion extends the survival of these patients to a median of up to
19–20 months according to RCT and meta-analysis of pooled data
[139]. Nonetheless, outcome prediction is heterogeneous for
BCLC B subclass patients, and has been reported to range from
around 36–45 months [165–167] for the best responders to
chemoembolization in recent series, to 11 months for the worst
scenario of untreated candidates (placebo arm of the SHARP
trial-BCLC B patients) [168]. A recent meta-analysis of RCT assess-
ing outcome of patients in the control arm suggests that ascites –
which contraindicates TACE treatment – is the worst prognostic
factor for this subclass [133].
Advanced HCC (BCLC stage C): Patients with cancer related-
symptoms (symptomatic tumors, ECOG 1–2), macrovascular
invasion (either segmental or portal invasion) or extrahepatic
spread (lymph node involvement or metastases) bear a dismal
prognosis, with expected median survival times of 6 months
[131,164], or 25% at 1 year [133]. Nonetheless, it is obvious that
this outcome varies according to the liver functional status and
other variables. For instance, patients with preserved liver func-
tion (Child–Pugh’s A class) have a median survival of 7 months
[168], while those with severe liver impairment (Child–Pugh’s B
class) present 5 months of median life expectancy. In 2006, there
was no FDA-approved ﬁrst line treatment for patients with
advanced HCC. This scenario has changed as a result of the data
reported showing survival beneﬁts from patients receiving
sorafenib – a multi tyrosine kinase inhibitor – in advanced cases
[168]. The results of this RCT represent a breakthrough in the
management of HCC, as it is discussed in the molecular targeted
therapies section of this document. Overall median survival in the
sorafenib arm was 10.7 months, ranging from 14.7 months in
BCLC B and 9.5 months in BCLC C patients.
End-stage HCC: Patients with end-stage disease are character-
ized by presentingwith tumors leading to a very poor Performance
Status (ECOG 3–4), which reﬂects a severe tumor-related disabil-
ity. Their median survival is 3–4 months [148] or 11% at 1-year
[133]. Similarly, Child–Pugh C patients with tumors beyond the
transplantation threshold also have a very poor prognosis.
Concept of treatment stage migration
A proportion of patients in each stage do not fulﬁl all the criteria
for the treatment allocation. In those cases, it is advised to offer
the patient the next most suitable option within the same stage
or the next prognostic stage. For instance, patients at BCLC A
failing local ablation should be offered chemoembolization.
Similarly, patients at BCLC B stage non-responding to chemoemb-
olization – at least two cycles of treatment – should be offered
sorafenib, as reported in the SHARP trial [168,169].
Reﬁnement of BCLC classiﬁcation
Some studies challenged the capacity of BCLC to properly provide
a ﬁne stratiﬁcation of patients for trial design. These studies
mostly included patients at BCLC C stage of the disease [170].
The panel of experts acknowledges that the range of survival
reported for patients at BCLC B (from 45 months to 11 months)
and C (from 11 months to 5 months) deserves to be addressed.Journal of Hepatology 201Further stratiﬁcation of patients within each class according to
liver function (Child–Pugh A versus B, or ascites), prognostic
molecular biomarkers or prognostic variables (ECOG, cancer inva-
siveness) should be explored.
Molecular classiﬁcation of HCC
Molecular classiﬁcation of cancer should aid in understanding the
biological subclasses and drivers of the disease and optimize ben-
eﬁts from molecular therapies and enrich trial populations. Few
molecular classiﬁcations have been proposed in cancer. One such
is the case of breast cancer, where Her2/nu status discriminates
subgroups of patients with different outcome and treatment
response to trastuzumab [171]. Similarly, EGFR mutational status
in non-small cell lung cancer identiﬁes a subgroup of responders
to tyrosine kinase inhibitors [172]. More recently, the fact that a
subgroup of patients with melanoma and BRAF mutations
respond to speciﬁc B-RAF inhibitors has deﬁned a new paradigm
and subclass in the management of this cancer [173].
In HCC, no molecular subclass has been reported as respond-
ing to speciﬁc targeted therapy. Nonetheless, clear advancements
in the understanding of the pathogenesis and molecular subclass-
es of the disease occurred during the last decade. From the bio-
logical standpoint, different tumoral classes have been
characterized including a Wnt subclass, a proliferation class (with
two subclasses: S1-TGF-beta and S2-EpCAM positive) and an
inﬂammation class [77,137,174,175]. Samples obtained from dif-
ferent parts of a given neoplastic nodule showed identical class
stratiﬁcation in 95% of cases [136]. Equally relevant, gene proﬁl-
ing of adjacent non-tumoral tissue deﬁnes two subgroups of
patients with good and poor outcome [137]. Thus, a portrait of
the ﬁeld effect is currently available, although further studies
are required to conﬁrm the prognostic signiﬁcance of these sub-
classes, and whether speciﬁc drivers within them can provide the
rationale for a more stratiﬁed medicine.Treatment
• Treatment allocation is based on the BCLC allocation 
system, and the levels of evidence of treatments 
summarized in Fig. 4
according to strength and magnitude of benefit are
In oncology, the beneﬁts of treatments should be assessed
through randomized controlled trials and meta-analysis. Other
sources of evidence, such as non-randomized clinical trials or
observational studies are considered less robust. Few medical
interventions have been thoroughly tested in HCC, in contrast
with other cancers with a high prevalence worldwide, such as
lung, breast, colorectal and stomach cancer. As a result, the
strength of evidence for most interventions in HCC is far behind
the most prevalent cancers worldwide. The level of evidence for
efﬁcacy according to trial design and end-points for all available
treatments in HCC and the strength of recommendations accord-
ing to GRADE are summarized in Fig. 4.
In principle, recommendations in terms of selection for different
treatment strategies are based on evidence-based data in circum-
stances where all potential efﬁcacious interventions are available.2 vol. 56 j 908–943 921
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Fig. 4. Representation of EASL–EORTC recommendations for treatment according to levels of evidence (NCI classiﬁcation [2]) and strength of recommendation
(GRADE system). RF, radiofrequency ablation; PEI, percutaneous ethanol injection; OLT, orthotopic liver transplantation; LDLT, living donor liver transplantation.
Clinical Practice GuidelinesMultidisciplinary HCC teams including hepatologists, surgeons,
oncologists, radiologists, interventional radiologists, pathologists
and translational researchers are encouraged to apply these guide-
lines. Strategic recommendations should be adapted to local regu-
lations and/or team capacities and cost–beneﬁt strategies.
Resection
• 
with solitary tumors and very well-preserved liver 
venous pressure gradient ≤10 mmHg or platelet count 
≥100,000 
(evidence 2A; recommendation 1B)
Anatomical resections are recommended
(evidence 3A; recommendation 2C)
• Additional indications for patients with multifocal tumors 
meeting Milan criteria (≤3 nodules ≤3 cm) or with mild 
portal hypertension not suitable for liver transplantation 
require prospective comparisons with loco-regional 
treatments
(evidence 3A; recommendation 2C) 
• Peri-operative mortality of liver resection in cirrhotic 
patients is expected to be 2-3%
• Neo-adjuvant or adjuvant therapies have not proven to 
improve outcome of patients treated with resection (or 
local ablation)
(evidence 1D; recommendation 2C)
• Tumor recurrence represents the major complication 
subsequent therapy allocation and outcome. In case 
of recurrence, the patient will be re-assessed by BCLC 
staging, and re-treated accordingly 
Resection is the first-line treatment option for patients
function, defined as normal bilirubin with either hepatic
of resection and the pattern of recurrence influences922 Journal of Hepatology 201Surgery is the mainstay of HCC treatment. Resection and
transplantation achieve the best outcomes in well-selected can-
didates (5-year survival of 60–80%), and compete as the ﬁrst
option in patients with early tumors on an intention-to-treat per-
spective [176,177]. Hepatic resection is the treatment of choice
for HCC in non-cirrhotic patients (5% of cases in the West, 40%
in Asia) [178,179], where major resections can be performed with
low rates of life-threatening complications and acceptable out-
come (5-year survival: 30–50%).
Modern standards of HCC resection in cirrhotic patients are
deﬁned by the panel as follows: expected 5-year survival rates
of 60%, with a peri-operative mortality of 2–3% and blood transfu-
sion requirements of less than 10% [102,157,180–182]. In fact,
peri-operative mortality has decreased from 15% in the 1980s to
3–5% in the majority of referral units. Some centers have reported
zero peri-operative mortality [176,183]. Blood loss is signiﬁcantly
associated with patient outcome and may be controlled both by
selecting patients with preserved liver functional reserve and by
applying intermittent inﬂow occlusion during the hepatic paren-
chymal transection. Nowadays the selection of candidates for
resection has been reﬁned, and both the surgical technique –
pre-resection imaging planning, ultrasonic dissector, intermittent
Pringle maneuvre, low central venous pressure maintenance, etc.
– and immediate post-operative management have been opti-
mized. These strategies have led to a decrease in blood transfusion
from 80% to 90% to less than 10% in two decades [183]. In addition,
the implementation of anatomic resections according to Couinaud
has ensured a surgical approach based on sound oncologic princi-
ples, although associated with modest decrease in early recur-
rence [184]. Anatomic resections aiming at 2 cm margins
provide better survival outcome than narrow resection margins
<1 cm [185] and are recommended only in case that the mainte-
nance of appropriate function to the remnant liver volume is
ensured. Retrospective studies linking anatomic resections and
better outcome should be interpreted with caution, due to the
propensity of performing wider interventions in patients with
well-preserved liver function. Thus, caution should be exercised
as the surgical effort is aimed at preservation of adequate hepatic2 vol. 56 j 908–943
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reserve through tailoring of the procedures to individual patients
and tumor characteristics – i.e. body size, central versus periphe-
ral location of tumor nodule and solitary large HCC (versus inﬁl-
trating tumor types).
Selection of the ideal candidates involves an adequate assess-
ment of the liver functional reserve and tumor extension. The
reﬁnement of assessment of liver function has moved from the
gross determination of Child–Pugh class to a more sophisticated
measurement of indocyanine green retention rate at 15 min
(ICG15) [186] or hepatic venous pressure gradient (HVPG)
P10 mmHg as a direct measurement of relevant portal hyperten-
sion [187]. This concept of portal hypertension as prognostic fac-
tor in patients undergoing resection has recently been validated in
Asia [182]. Surrogatemeasures of portal hypertension include two
variables: platelet count below 100,000/mm3 associated with
splenomegaly, being the spleen size the less among clinical
parameters associated with portal hypertension [188]. Platelet
count has been recently conﬁrmed as independent predictor of
survival in resected HCC cases [189]. In line with these consider-
ations, although the extensive assessment of each component of
portal hypertension (HVPG, esophageal varices, splenomegaly
and platelet count) is recommended before surgery, platelet count
remains the most accessible parameter of portal hypertension
available. In practice, selection of patients with HVPG <10 mmHg
or absence of surrogates of portal hypertension (esophageal vari-
ces, or splenomegaly with platelet count <100.000/mm3) lead to a
resectability rate of less than 10% [99]. Expansion of these restric-
tive criteria by applying MELD score of 610 needs to be prospec-
tively validated with a survival end-point [189].
Some groups apply pre-operative portal vein embolization
(PVE) of the branches supplying the portion of the liver to be
resected in order to increase the residual liver volume if a major
resection is envisioned [183,190]. This approach is associated
with a complication rate of 10–20% and occurrence of severe
portal hypertension in 1% of cirrhotic patients [191]. However,
the effectiveness of PVE in the frame of HCC in cirrhosis has
not yet been properly tested in large controlled studies. Finally,
an increasing number of data are collected on laparoscopic
video-assisted hepatic resection, as an alternative non-invasive
approach aimed at preventing liver deterioration compared to
open approaches. The positive results reported for speciﬁc tumor
locations in cohort series [192] need prospective comparison
with traditional laparotomic resection before any change in
current practice is made.
In patients properly selected according to liver functional sta-
tus, the main predictors of survival are tumor size, tumor number
presence of microsatellites and vascular invasion [176]. Tumor
extension should be assessed by latest generation CT scan or
MRI. Intraoperative ultrasonography (IOUS) enables the detection
of nodules between 0.5 and 1 cm and is considered the standard
of care for discarding the presence of additional nodules and to
guide anatomical resections [193]. The Japanese Nationwide Sur-
vey has shown that a cut-off below 2 cm is an independent pre-
dictor of survival in a series of thousands of patients [194]. Five
year survival rates for patients with HCC 62 cm was of 66%, com-
pared with 52% for tumors 2–5 cm and 37% for tumors >5 cm.
Multinodularity also predicts survival, with 5-year survival rates
after resection of single tumors of 57% and 26% for three or more
nodules, respectively. Recently, some referral centers reported 5-
year survival rates above 50% in patients undergoing resection for
multiple tumors fulﬁling Milan criteria (up to 3 nodules 63 cm)Journal of Hepatology 201not suitable for transplantation [180–182]. The positive results
reported need further comparison of resection with loco-regional
therapies prior to being adopted by these guidelines.
Vascular invasion is a known predictor of recurrence and sur-
vival, directly associated with histological differentiation, degree
and size of the main nodule. Characteristically, microscopic vas-
cular invasion involves 20% of tumors of 2 cm in diameter, 30–
60% of cases in nodules 2–5 cm and up to 60–90% in nodules
above 5 cm in size [176]. A more accurate observation of micro-
vascular invasion has led to the identiﬁcation of invasion of a
muscular wall vessel or of more than 1 cm beyond the tumor
edge as the 2 worst risk factors for prognosis [157]. Outcome of
patients with single resected tumors varied from median survival
87 months for patients with no vascular invasion, 38–
71 months for those with microvascular invasion with 0–1 risk
factors, and 8–12 months for those with microvascular invasion
and 2 risk factors or macrovascular invasion. This classiﬁcation
requires external validation [157].
Adjuvant treatments to prevent recurrence
Tumor recurrence complicates 70% of cases at 5 years, reﬂecting
either intrahepatic metastases (true recurrences) or the develop-
ment of de novo tumors [161,157,180–182,195,196]. These enti-
ties can be differentiated by means of comparative genomic
hybridization, integration pattern of hepatitis B virus, DNA ﬁn-
gerprinting using loss of heterozygosity assays, or DNA micro-
array studies [197]. No clinical deﬁnition of both entities has
been established, but the cut-off of 2 years has been adopted to
grossly classify early and late recurrences [149,198].
Several strategies to prevent and treat recurrence have been
tested in the setting of randomized studies. Almost all published
RCT have been conducted in Asia. Interferon is the most
frequently evaluated drug so far. Different meta-analyses have
evaluated the effect of adjuvant interferon treatment [199–201].
In one analysis including 13 studies (9 small RCT) there was a
signiﬁcant improvement in recurrence-free survival with inter-
feron (estimated 3-year RFS of 54% versus 30% of placebo)
[200]. Similar results were reported in other studies, in which
different patient populations were studied. In the ﬁrst Western
RCT assessing interferon-alpha in 150 patients, negative results
were obtained, but a positive trend in preventing de novo late
recurrences was identiﬁed, providing the rationale for assessing
this strategy in future research [181]. Considering the available
information, the panel does not recommend adjuvant interferon
due to the lack of signiﬁcant patient numbers and partially
conﬂicting data. Interestingly, recently miR-26 was identiﬁed as
a potential marker predicting response to adjuvant interferon
therapy [135]. Future studies in the adjuvant setting should
include this type of molecular marker to more precisely categorize
patients responding to adjuvant therapy.
Other strategies tested include chemotherapy, chemoemboli-
zation, internal radiation, immune therapies and retinoids. Adju-
vant chemoembolization and chemotherapy do not bring any
beneﬁt in terms of prevention of relapse [202]. Internal radia-
tion with 131I-labeled lipiodol showed a positive effect in a
small trial and cohort study [203,204]. Adoptive immunother-
apy with activated lymphocytes with interleukin-2 reduced ﬁrst
recurrence in a trial with 150 patients (3-year recurrence: 33%
versus 48% in the control group) [205]. A similar beneﬁcial
effect, described with retinoids and vitamin K2 preventing de2 vol. 56 j 908–943 923
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novo tumors, has not been recently conﬁrmed in the setting of
two large RCT studies [206–208]. Overall, according to a recent
Cochrane systematic review, 12 RCTs were identiﬁed with less
than 1000 patients randomized leading to an unclear body of
evidence for efﬁcacy of any of the adjuvant and neo-adjuvant
protocols reviewed [209]. Thus, none of these strategies are rec-
ommended in clinical practice.
Larger trials with a lower risk of systematic error will have to
be conducted according to previously reported guidelines [149].
The primary end-point of the studies should be time to recurrence
or overall survival. Due to the lack of proven effective treatments,
it is justiﬁed to randomize patients to an untreated control arm.
Selection of patients should be based on the BCLC staging system,
and stratiﬁcation prior to randomization should be done accord-
ing to tumor size, number of nodules/satellites, and vascular inva-
sion. Due to the nature of these investigations, multi-institutional
studies are required. The positive results reported with sorafenib
for advanced HCC warrant an international study in the adjuvant
setting with this multikinase inhibitor.Liver transplantation
• 
treatment option for patients with single tumors less than 
5 cm or ≤3 nodules ≤3 cm (Milan criteria) not suitable for 
resection
(evidence 2A; recommendation 1A)
• Peri-operative mortality and one-year mortality 
are expected to be approximately 3% and ≤10%, 
respectively  
• Extension of tumor limit criteria for liver transplantation 
for HCC has not been established. Modest expansion 
of Milan criteria applying the “up-to-seven” in patients 
without microvascular invasion achieves competitive 
outcomes, and thus this indication requires prospective 
validation
(evidence 2B; recommendation 2B)
• Neo-adjuvant treatment can be considered for loco-
regional therapies if the waiting list exceeds 6 months 
due to good cost-effectiveness data and tumor response 
rates, even though impact on long-term outcome is 
uncertain 
(evidence 2D; recommendation 2B)
• Down-staging policies for HCCs exceeding conventional 
criteria cannot be recommended and should be explored 
in the context of prospective studies aimed at survival 
and disease progression end-points 
(evidence 2D; recommendation 2C) 
RECIST criteria
• Living donor liver transplantation is an alternative option 
in patients with a waiting list exceeding 6-7 months, and 
offers a suitable setting to explore extended indications 
within research programs
(evidence 2A; recommendation 2B) 
Liver transplantation is considered to be the first-line
Assessment of downstaging should follow modified924 Journal of Hepatology 201Liver transplantation is the ﬁrst treatment choice for patients
with smallmultinodular tumors (63 nodules63 cm) or thosewith
single tumors 65 cm and advanced liver dysfunction. Theoreti-
cally, transplantation may simultaneously cure the tumor and
the underlying cirrhosis. The broad selection criteria applied two
decades ago led to poor results in terms of recurrence (32–54% at
5 years) and survival (5-year survival <40%), but allowed the iden-
tiﬁcation of the best candidates for this procedure [210,211]. Fol-
lowing this concept, some pioneering groups selecting ‘‘optimal
candidates’’ reported 70% 5-year survival with a recurrence rate
below 15% [161,212–215]. In a landmarkmanuscript the so-called
Milan criteria were established for patients with a single HCC
65 cmor up to three nodules63 cm [212]. Following these criteria
and according to modern standards, peri-operative mortality, 1
and 5-year mortality are expected to be 3%, 610%, and 630%,
respectively. Data on 10-year survival is scarce, and the panel
endorses the practice of reporting these ﬁgures for surgical inter-
ventions following the intention-to-treat principle, in order to bet-
ter discriminate differences in outcome between resection and
transplantation not apparent at the conventional 5-year cut-off.
A recent systematic review including 90 studies, comprising a
total of 17,780 patients over 15 years, identiﬁed the Milan criteria
as an independent prognostic factor for outcome after liver trans-
plantation [177]. Overall 5-year survival of patients within the
Milan criteria (65–78%) was similar compared with non-HCC
indications according to European (ELTR) and American registries
(OPTN) (65–87%) [177,216,217]. ELTR reports 10-year survival
rates of around 50% in more than 12,000 cases performed
[216]. As a consequence of their success, the Milan criteria have
been integrated in the BCLC staging system [148,149] and in
the UNOS pre-transplant staging for organ allocation in the US
[218], and remain the benchmark for any other prognostic crite-
ria proposed for expanding the indication to liver transplantation
in cirrhotic patients with HCC [219].
The major drawback of liver transplantation as a treatment of
HCC is the scarcity of donors. Increases in waiting time have led
to 20% of transplant candidates dropping out of the lists before
receiving the procedure, thus jeopardizing the outcome if ana-
lyzed according to intention-to-treat [161,220]. Four concepts
have been addressed by the panel in the context of transplanta-
tion for patients with HCC: (1) priority and delisting policies;
(2) neoadjuvant treatments in the waiting list; (3) extension of
criteria and downstaging for transplantation; and (4) living donor
liver transplantation. The recently reported International Consen-
sus Conference on Liver Transplantation has been instrumental in
complementing the current guidelines [219].
Priority and delisting policies
UNOS developed a priority system to manage waiting lists for
transplantation based on the MELD score [218], which was orig-
inally generated to predict 3-month survival in patients with
End-Stage Liver Disease [221]. Since MELD is unable to predict
the drop-out rate of patients with HCC, several priority scores
have been assigned to these patients ranging from 24 (single
<2 cm) and 29 points (single 2–5 cm or 3 nodules each <3 cm)
in early proposals to none and 22 points respectively in the cur-
rent era. The main difﬁculty for establishing priority policies is to
deﬁne the at-risk patients for drop-out, which in some studies are
identiﬁed as those patients with multinodular tumors, neoadju-
vant treatment failures or those with baseline serum AFP levels2 vol. 56 j 908–943
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>200 ng/ml or steady increase of >15 ng/ml/month [140]. At the
opposite end of the spectrum, some patients with UNOS-T1
tumor (single <2 cm) may beneﬁt from alternative non-trans-
plant treatments and avoid futile transplantation, at least until
recurrence occurs [222].
Strategies advocating ‘‘salvage transplantation’’ approaches in
low-risk populations should be investigated in prospective stud-
ies focused on intention-to-treat analysis and survival beneﬁt, as
they also depend on waiting time and local scenarios of donor
availability. Similarly, patients undergoing resection with patho-
logical high risk of recurrence have been proposed to be enlisted
for liver transplantation [223]. Since waiting times vary signiﬁ-
cantly worldwide, it is recommended that policymakers modu-
late priority policies along with these variables.
There is even less information available about policies of
delisting. The current panel recommends putting on hold those
patients whose HCC progressed beyond Milan while on the wait-
ing list and explore neo-adjuvant therapies for them. The panel
recommends delisting those patients developing macrovascular
invasion or extrahepatic spread.
Neo-adjuvant treatments in the waiting list
Adjuvant therapies for patients within the Milan criteria while on
the waiting list are used in most centers to prevent tumor pro-
gression. Robust data from RCT are lacking and thus, the potential
beneﬁts advocated for local ablation or chemoembolization are
derived from observational studies and cost–effectiveness analy-
ses. The main studies assessing neo-adjuvant treatments are case
series, case–control studies and cohort studies showing that RFA
achieves the higher rates of complete necrosis (12–55%)
[224,225] compared with TACE (22–29%) [226–228].
The impact of these treatments on drop-out rate, recurrence
and survival is only estimated from non-randomized studies.
From initial studies reporting drop-out rates, an actuarial proba-
bility of 15–30% at 1 year was established [161,220]. Among the
case series and cohort studies reported, some investigations sug-
gest a favorable impact of treatment in decreasing the dropout
rate to levels ranging from 0% to 25% [222,224]. Similarly, since
treatments on the waiting list have been studied in an uncon-
trolled fashion, their effects on survival after LT are difﬁcult to
assess. Since the publication of the seminal study [226], case–
control studies including index treated cases and matched con-
trols indicate similar survival rates as untreated individuals
[227,228]. Markov-based cost–effectiveness analysis, on the con-
trary, pointed to beneﬁts for neo-adjuvant treatments when
waiting times exceed 6 months [229]. The use of sorafenib for
the treatment of UNOS-T2 patients in the waiting list is not rec-
ommended according to the small pilot studies and cost–effec-
tiveness studies published so far [230,231]. The real effect of
loco-regional or molecular therapies on patient outcomes and
on global gains of life expectancy from a societal perspective is
uncertain. Therefore, considering the strength of evidence avail-
able, it is recommended to treat patients waiting for transplant
with local ablation, and as a second choice with chemoemboliza-
tion when waiting times are estimated to exceed 6 months.
Extension of indications and downstaging for liver transplantation
Analysis of the expansion of criteria beyond Milan and downstag-
ing to Milan has been extensively explored. In summary, theJournal of Hepatology 201main concept is that to establish a new policy allowing expansion
of criteria for transplantation, it is essential to develop robust
data for the speciﬁc category of patients included in the proposed
expansion. Novel criteria might have a major impact on all trans-
plant programs and the data needed to support any change
should be impeccable. In addition, the impact of the expansion
on the non-HCC patients waiting for liver transplantation should
be taken into account.
The current understanding is that expansion to UCSF criteria
(single nodule 66.5 cm or 2–3 nodules 64.5 cm and total tumor
diameter 68 cm) – which involves around 5–10% of all enlisted
patients [220,232] – has already been challenged from the path-
ological point of view by the up-to-seven criteria (i.e. those HCCs
having the number 7 as the sum of the size of the largest tumor
and the number of tumors) [233] This pathology-based proposal
has been recently validated in an independent series [234]. The
major concerns about the expansion proposals are the lack of
speciﬁc data on overall survival and drop-out rate on the waiting
list for the patients outside the current criteria but fulﬁling the
expanded criteria. Other recent studies challenging the Milan cri-
teria have proposed different algorithms to optimize patient
selection. Nonetheless, 5-year outcome prediction could vary
from 70% to 40% according to the presence of microvascular
invasion. Thus, preoperative markers of vascular invasion would
be required prior to adopting these criteria. In a meta-analysis to
evaluate tumor size and nodules, a cut-off of sum of diameters
above 10 cm was considered to increase fourfold the risk of
death [235], while a combination of tumor volume and AFP lev-
els was considered the best strategy in other studies [140,141].
Molecular markers, such as allelic imbalance reﬂecting chromo-
somal instability, have also been shown to predict recurrence
after transplantation [236]. Considering the strength of the evi-
dence, it is recommended not to allow the extension of the cri-
teria for transplant eligibility, except in the context of research
protocols.
Regarding downstaging, there is not a single RCT, large
case–control study or large well-designed cohort study avail-
able on patients treated consistently and properly followed.
Small prospective studies suggest that downstaging to Milan
criteria from patients with liver-only disease treated by radio-
frequency or chemoembolization achieves 5-year survival out-
comes similar to those within Milan [237,238]. It is unclear
whether downstaging therapies yield measurable anti-cancer
effects or only provide a time frame in which to evaluate the
natural history of HCC, with the ultimate risk of transforming
pre-transplant drop-outs into post-transplant recurrences
[239,240]. There is no clear upper limit for eligibility of down-
staging [240].
Considering the current data, downstaging of patients beyond
Milan criteria cannot be adopted as a tool to reﬁne patient selec-
tion and further research is required. This research should be
based on the principle that 5-year survival outcomes of patients
undergoing transplantation after successful downstaging should
be similar to those of patients transplanted following Milan crite-
ria [219]. The panel considers, though, that a special policy
should be adopted for patients already on the waiting list for liver
transplantation with tumors progressing beyond Milan and liver-
only disease. In this special circumstance, as stated above, it is
recommended to place the candidate on hold until downstaging
by local ablation or chemoembolization is achieved and main-
tained for a period of at least 3 months.2 vol. 56 j 908–943 925
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Living donor liver transplantation
Living donor liver transplantation (LDLT) using the right hepatic
lobe of a healthy donor has emerged as an alternative to deceased
liver transplantation [241,242]. In 2000, there was great enthusi-
asm for LDLT, and it was estimated that it would represent a sig-
niﬁcant proportion of the patients transplanted with HCC [243].
Unfortunately, the associated risks of death (estimated in 0.3%)
and life-threatening complications (2%) for the healthy donor
have diminished the interest of the transplant community [244–
246]. Currently, LDLT comprises less than 5% of adult liver trans-
plants, signiﬁcantly less than in kidney transplantation where liv-
ing donors represent 40% of all cases performed [246]. The risks
and beneﬁts of LDLT should take into account both donor and reci-
pient, a concept known as double equipoise [219,247,248]. Due to
the complexity of the procedure, LDLT must be restricted to cen-
ters of excellence in hepatic surgery and transplantation.
Outcome results with LDLT compared with deceased LT have
been controversial. Although some studies suggested that LDLT
was associated with higher risk of recurrence, these data have
not been conﬁrmed [249,250]. Cost–effectiveness studies sug-
gested that LDLT can be offered to patients with HCC if the wait-
ing list exceeds 7 months [248], a policy adopted by the panel.
Some authors recommend a period of observation prior trans-
plant of 3 months, in order to avoid transplanting potentially
aggressive tumors, a proposition that needs to be conﬁrmed in
further investigations [250,251]. LDLT has been proposed as an
ideal setting to explore extended indications for HCC, considering
the lack of graft allocation and priority policies [252]. Therefore,
the panel does not recommend this procedure for any extended
indication, except in the context of research studies.Local ablation
• Local ablation with radiofrequency or percutaneous 
ethanol injection is considered the standard of care for 
patients with BCLC 0-A tumors not suitable for surgery 
(evidence 2A; recommendation 1B)
Other ablative therapies, such as microwave or 
cryoablation, are still under investigation
• Radiofrequency ablation is recommended in most 
instances as the main ablative therapy in tumors less 
disease 
(evidence 1iD; recommendation 1A)
Ethanol injection is recommended in cases where 
radiofrequency ablation is not technically feasible 
(around 10-15%)
• In tumors <2 cm, BCLC 0, both techniques achieve 
complete responses in more than 90% of cases 
with good long-term outcome. Whether they can be 
considered as competitive alternatives to resection is 
uncertain
(evidence 1iA; recommendation 1C)
than 5 cm due to a significantly better control of the926 Journal of Hepatology 201Local ablation is considered the ﬁrst line treatment option for
patients at early stages not suitable for surgical therapies. Over
the past 25 years, several methods for chemical or thermal tumor
destruction have been developed and clinically tested [253]. The
seminal technique used is percutaneous ethanol injection (PEI),
which induces coagulative necrosis of the lesion as a result of cel-
lular dehydration, protein denaturation, and chemical occlusion
of small tumor vessels. Subsequently, thermal ablative therapies
emerged, and are classiﬁed as either hyperthermic treatments
(heating of tissue at 60–100 C) – including radiofrequency abla-
tion (RFA), microwave ablation, and laser ablation – or cryoabla-
tion (freezing of tissue at 20 C and 60 C). Most procedures
are performed using a percutaneous approach, although in some
instances ablation with laparoscopy is recommended. PEI is a
well-established technique for the treatment of nodular-type
HCC that achieves complete necrosis in 90% of tumors <2 cm,
70% in those of 2–3 cm and 50% in those between 3 and 5 cm
[162,253,254]. It has been speculated that ethanol diffusion is
blocked either by the intratumoral ﬁbrotic septa and/or the
tumor capsule. This undermines the curative capacity of this
technique, particularly in tumors larger than 2 cm. The recent
introduction of a speciﬁc device for single-session PEI, a multi-
pronged needle with three retractable prongs, has resulted in a
rate of sustained complete response of 80–90% in tumors smaller
than 4 cm [255]. In patients with Child–Pugh A cirrhosis and
early-stage tumors, treatment with PEI has been shown to result
in 5-year survival rates of 47–53% [256,257]. The major limitation
of PEI is the high local recurrence rate, which may reach 43% in
lesions exceeding 3 cm [258]. Another chemical ablation tech-
nique, percutaneous acetic acid injection (PAI), has not offered
substantial advantages to PEI [259].
RFA has been the most widely assessed alternative to PEI for
local ablation of HCC. The energy generated by RF ablation
induces coagulative necrosis of the tumor producing a safety ring
in the peritumoral tissue, which might eliminate small-unde-
tected satellites. Consistent with previous studies, RF requires
fewer treatment sessions to achieve comparable anti-tumoral
effects. Five randomized controlled trials have compared RFA ver-
sus PEI for the treatment of early-stage HCC. These investigations
consistently showed that RFA has a higher anticancer effect than
PEI, leading to a better local control of the disease (2 year local
recurrence rate: 2–18% versus 11–45%) [260–264]. The assess-
ment of the impact of RFA on survival has been more controver-
sial. Survival advantages favouring RF versus PEI were identiﬁed
in the Japanese study including 232 patients [261], but no differ-
ences in survival were reported in the two European RCT
[263,264]. Two additional RCT from the same group reported sur-
vival advantages in the subgroup analysis of tumors larger than
2 cm favouring RF compared with either PEI or PAI [260,262].
In patients with early-stage HCC treated with percutaneous abla-
tion, long-term survival is inﬂuenced by multiple different inter-
ventions, given that a high percentage of patients will develop
recurrent intrahepatic HCC nodules within 5 years of the initial
treatment and will receive additional therapies. Nevertheless,
three independent meta-analyses including all RCT, have con-
ﬁrmed that treatment with RFA offers a survival beneﬁt as com-
pared with PEI in tumors larger than 2 cm [265–267]. The main
drawback of RF is its higher rates of major complications (4%;
95% CI, 1.8–6.4%) compared to PEI (2.7%; 95% CI, 0.4–5.1%)
[267,268].2 vol. 56 j 908–943
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Considering the reported data, the best results obtained in ser-
ies of HCC patients treated by RFA provide 5-year survival rates of
40–70% [269,270], and even beyond in highly selected candidates
[142]. The best outcomes have been reported in Child–Pugh A
patients with small single tumors, commonly less than 2 cm in
diameter [159,162]. Independent predictors of survival are initial
complete response, Child–Pugh score, number or size of nodules,
and base-line alpha-fetoprotein levels. Thus, Child–Pugh A
patients with non-surgical small tumors – that are expected to
achieve complete responses – are the ideal candidates to RFA.
Around 10–15% of tumors with difﬁcult-to-treat locations can
be approached by PEI [271]. Treatment of patients with larger
tumors (3–5 cm), multiple tumors (3 nodules <3 cm) and
advanced liver failure (Child–Pugh B) along with combination of
both techniques could be reasonable on an individual basis.
Although these treatments provide good results, they are unable
to achieve response rates and outcomes comparable to surgical
treatments, even when applied as the ﬁrst option [194].
An open question is whether RFA can compete with surgical
resection as a ﬁrst-line treatment for patients with small, solitary
HCC. Two RCT have been reported with opposite results
[272,273].While the ﬁrst one did not identify outcomedifferences,
the second trial suggested a survival advantage for surgical resec-
tion. Uncontrolled investigations have reported similar results for
resection and RFA in BCLC 0 patients [159]. Further trials should
overcome methodological issues which prevent the drawing of
robust conclusions from the current studies. In addition, while
complete removal of neoplastic tissue (R0) is common after surgi-
cal resection, some indications highlight the need to proceed with
caution after analyzing the pathological specimens of tumors
ablated with RFA. Complete tumor necrosis of less than 50% has
been reported in tumors >3 cm because of the heat loss due to per-
fusion-mediated tissue cooling within the area ablated [274]. In
addition, HCC tumors in a subcapsular location or adjacent to the
gallbladder have a higher risk of incomplete ablation [275] or
major complications [268,276,277]. Thus, at this point there are
no data to support RFA as a replacement of resection as the ﬁrst-
line treatment for patients with early HCC (BCLC A) stage.Treatments under investigation
Microwave ablation, laser ablation and cryoablation have been
proposed for local ablation in HCC. Microwave ablation has an
important advantage compared to RFA, which is that treatment
efﬁcacy is less affected by vessels located in the proximity of
the tumor. Initial studies were limited by inducing a small vol-
ume of coagulation [278], and led to suboptimal performances
when compared with RFA in the sole reported RCT [279]. Newer
devices remain to be tested. Regarding laser ablation, no RCT has
been published so far. In a recent multicenter retrospective anal-
ysis including 432 nonsurgical patients with early-stage HCC, 5-
year overall survival was 34% (41% in Child–Pugh class A
patients) [280]. Cryoablation had limited application in HCC,
and no RCT have been reported [281]. The complication rate is
not negligible, particularly because of the risk for ‘‘cryoshock’’, a
life threatening condition resulting in multiorgan failure, severe
coagulopathy and disseminated intravascular coagulation follow-
ing cryoablation.
Non-Chemical Non-Thermal Ablation Techniques are currently
undergoing clinical investigation. Irreversible electroporation isJournal of Hepatology 201currently in clinical evaluation, after pre-clinical positive
approach [282]. HIFU is a novel ablative approach reported
in cohorts of patients with small tumors, but no randomized
studies are available [283]. Light-activated drug therapy uses
light-emitting diodes to activate talaporﬁn sodium in HCC after
intravenously administration. Phase 3 studies with this therapy
are ongoing [284].Chemoembolization and transcatheter therapies
• Chemoembolization is recommended for patients with 
BCLC stage B, multinodular asymptomatic tumors 
without vascular invasion or extra hepatic spread 
(evidence 1iiA; recommendation 1A)
The use of drug-eluting beads has shown similar 
response rates than gelfoam-lipiodol particles 
associated with less systemic adverse events 
(evidence 1D; recommendation 2B)
Chemoembolization is discouraged in patients 
with decompensated liver disease, advanced liver 
dysfunction, macroscopic invasion or extrahepatic 
spread
(evidence 1iiA; recommendation 1B)
Bland embolization is not recommended
• Internal radiation with 131I or 90Y glass beads has shown 
cannot be recommended as standard therapy. Further 
research trials are needed to establish a competitive 
(evidence 2A; recommendation 2B)
• Selective intra-arterial chemotherapy or lipiodolization 
are not recommended for the management of HCC 
(evidence 2A; recommendation 2B)
• External three-dimensional conformal radiotherapy is 
under investigation, and there is no evidence to support 
this therapeutic approach in the management of HCC 
(evidence 3A; recommendation 2C) 
promising anti-tumoral results with a safe profile, but
efficacy role in this populationChemoembolization
Chemoembolization (TACE) is the most widely used primary
treatment for unresectable HCC [160,165,194], and the recom-
mended ﬁrst line-therapy for patients at intermediate stage of
the disease [56,139,149]. HCC exhibits intense neo-angiogenic
activity during its progression. The rationale for TACE is that
the intra-arterial infusion of a cytotoxic agent followed by
embolization of the tumor-feeding blood vessels will result in
a strong cytotoxic and ischemic effect. TACE should be distin-
guished from chemo-lipiodolization – delivery of an emulsion
of chemotherapy mixed with lipiodol –, bland transcatheter
embolization (TAE), where no chemotherapeutic agent is deliv-
ered, and intra-arterial chemotherapy, where no embolization
is performed. Details on the distinct types and deﬁnitions of2 vol. 56 j 908–943 927
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image-guided transcatheter embolization have been reviewed
elsewhere [285,286].
Conventional chemoembolization (TACE)
This procedure combines transcatheter delivery of chemother-
apy emulsioned with lipiodol followed by vascular stagnation
achieved with embolic agents. Chemoembolization achieves
partial responses in 15–55% of patients, and signiﬁcantly delays
tumor progression and macrovascular invasion. The survival
beneﬁt of TAE or chemoembolization has been the subject of
a few RCT, which provided contradictory results [287–293].
Survival beneﬁts were obtained in two studies [292,293], one
of which identiﬁed treatment response as an independent
predictor of survival [293]. Meta-analysis of these seven RCT,
including a total of 516 patients, showed a beneﬁcial survival
effect of embolization/chemoembolization in comparison to
the control group [139]. Sensitivity analysis showed a signiﬁ-
cant beneﬁt of chemoembolization with cisplatin or doxorubi-
cin in four studies, but none with embolization alone in three
studies [139]. Overall, the median survival for intermediate
HCC cases is expected to be around 16 months, whereas after
chemoembolization the median survival is about 20 months.
As a result of these investigations, TACE has been established
as the standard of care for patients who meet the criteria for
the intermediate-stage of the BCLC staging system, i.e. those
with multinodular HCC, absence of cancer-related symptoms
and no evidence of vascular invasion or extrahepatic spread.
Recently, a meta-analysis by Cochrane investigators has
challenged the efﬁcacy of TACE [294]. Several biases contained
in this approach, including the use of trials with inappropriate
control arms or target populations leading to poor outcomes,
diminish any impact of this investigation. The beneﬁts of
combining TACE with local ablation procedures or systemic
therapies are under investigation.
The beneﬁts of chemoembolization should not be offset by
treatment-induced liver failure. Treatment-related deaths are
expected in less than 2% of cases if proper selection of candi-
dates is in place. The best candidates are patients with pre-
served liver function and asymptomatic multinodular tumors
without vascular invasion or extrahepatic spread [285,293].
Macroscopic vascular invasion of any type and extrahepatic
spread are major contraindications for chemoembolization.
One positive trial showed no beneﬁt in the subgroup analysis
restricted to patients presenting with portal vein invasion
[292]. Liver functional reserve is also a critical component for
a careful selection. Patients should present relatively well-
preserved liver function (mostly Child–Pugh A or B7 without
ascites), while those with liver decompensation or more
advanced liver failure should be excluded since the ischemic
insult can lead to severe adverse events [289]. Absolute and
relative contraindications for chemoembolization have been
reviewed elsewhere [169]. There is no good evidence for
which is the best chemotherapeutical agent and the optimal
re-treatment strategy, even though it is recommended to apply
the procedures 3–4 times per year and to use doxorubicin or
cisplatin as the standard chemotherapy. More intense regimes,
i.e. TACE every 2 months, might induce liver failure in an
unacceptable proportion of patients [289]. Superselective chemo-
embolization is recommended to minimize the ischemic insult
to non-tumoral tissue.928 Journal of Hepatology 201Chemoembolization with Drug-Eluting Beads (TACE-DEB)
Strategies to improve anti-tumoral activity and clinical beneﬁts
with chemoembolization have been launched. The ideal TACE
scheme should allow maximum and sustained intratumoral
concentration of the chemotherapeutic agent with minimal
systemic exposure, along with calibrated tumor vessel obstruc-
tion. Embolic microspheres have the ability to sequester che-
motherapeutic agents and release them in a controlled mode
over a 1-week period. This strategy has been shown to
increase the local concentration of the drug with negligible
systemic toxicity [166]. A randomized phase II study compar-
ing TACE and TACE-DEB reported a signiﬁcant reduction in
liver toxicity and drug-related adverse events for the latter
arm, associated with a non-signiﬁcant trend of better antitu-
moral effect [295].
Radioembolization and external radiation
Radioembolization is deﬁned as the infusion of radioactive sub-
stances such as Iodine-131 (131I)-labeled lipiodol [296] or micro-
spheres containing Yttrium-90 (90Y) [297–299] or similar agents
into the hepatic artery. Given the hypervascularity of HCC, intra-
arterially-injected microspheres will be preferentially delivered
to the tumor-bearing area and selectively emit high-energy,
low-penetration radiation to the tumor. A seminal RCT compar-
ing chemoembolization versus internal radiation with 131I has
not been followed by additional investigations [296]. Currently,
the most popular radioembolization technique uses microspheres
coated with 90Y, a ß-emitting isotope. This treatment requires a
third level specialized center with sophisticated equipment and
trained interventional radiologists. Severe lung shunting and
intestinal radiation should be prevented prior to the procedure.
Due to the minimally embolic effect of 90Y microspheres, treat-
ment can be safely used in patients with portal vein thrombosis
[298].
Cohort studies reporting long-term outcomes showed a
median survival time of 17.2 months for patients at intermedi-
ate stages [297] and 12 months for patients at advanced
stages and portal vein invasion [298–300]. Objective response
rates range from 35% to 50% [297–299]. Around 20% of
patients present liver-related toxicity and 3% treatment-related
death [297]. Despite the amount of data reported, there are no
RCT testing the efﬁcacy of 90Y radioembolization compared
with chemoembolization or sorafenib in patients at intermedi-
ate or advanced stage, respectively. Further research trials
are needed to establish a competitive efﬁcacy role in these
populations.
Other loco-regional treatments
The use of conventional external-beam radiation therapy
in HCC treatment has been limited by the low radiation
tolerance of the cirrhotic liver, which often resulted in
radiation-induced liver disease, previously known as radia-
tion-induced hepatitis [301]. The beneﬁts of external three-
dimensional conformal radiotherapy have only been tested
in uncontrolled investigations [302]. There is no scientiﬁc evi-
dence to recommend these therapies as primary treatments
of HCC and further research testing modern approaches is
encouraged.2 vol. 56 j 908–943
JOURNAL OF HEPATOLOGY
Systemic therapies
• Sorafenib is the standard systemic therapy for HCC. It is 
indicated for patients with well-preserved liver function 
(Child-Pugh A class) and with advanced tumors (BCLC C)
or those tumors progressing upon loco-regional 
therapies
(evidence 1iA; recommendation 1A)
• There are no clinical or molecular biomarkers available 
to identify the best responders to sorafenib
(evidence 1A; recommendation 2A)
• Systemic chemotherapy, tamoxifen, immunotherapy, 
anti-androgen, and herbal drugs are not recommended 
for the clinical management of HCC patients
(evidence 1-2A; recommendation 1A/B)
• There is no available second-line treatment for patients 
with intolerance or failure to sorafenib. Best supportive 
care or the inclusion of patients in clinical trials is 
recommended in this setting
(recommendation 2B)
• 
alleviate pain in patients with bone metastasis
(evidence 3A; recommendation 2C)
 
• Patients at BCLC D stage should receive palliative 
support including management of pain, nutrition 
and psychological support. In general, they should 
not be considered for participating in clinical trials 
(recommendation 2B)
In specific circumstances, radiotherapy can be used toMolecular pathogenesis and targets for therapies
Molecular targeted therapies have changed the landscape of
cancer management. Around 20 molecular targeted therapies
have been approved during recent years for patients with
breast, colorectal, non-small cell lung, renal cancer and HCC,
among other malignancies [164,303]. Recently a multikinase
inhibitor, sorafenib, has shown survival beneﬁts in patients
with advanced HCC [168]. This advancement represents a
breakthrough in the treatment of this complex disease, and
proves that molecular therapies can be effective in this cancer.
A better understanding of the molecular hepatocarcinogenesis
is critical for identifying novel targets and oncogenic addition
loops [304–306]. No pathognomonic molecular mechanism or
single dominant pathway exists in hepatocarcinogenesis and
this explains why a single-targeted agent will not achieve sus-
tained complete response in HCC. Consequently, it is conceiv-
able to inhibit signals at different levels of one of the main
pathways, or to inhibit two or three different pathways at the
same time.
Hepatocarcinogenesis is a complex multistep process where
multiple signaling cascades are altered leading to a heteroge-
neous biological portrait of the disease [304–306]. Although no
oncogenic addition loop deﬁning growth dependence for anyJournal of Hepatology 201subclass of HCC has been deﬁned, several signaling pathways
have been implicated in tumor progression and dissemination:
(1) Vascular growth factor (VEGF) signaling is the cornerstone of
angiogenesis in HCC, and high level ampliﬁcations have
been identiﬁed [175,307]. VEGFR signaling can be targeted
either by the monoclonal antibody bevacizumab directed
against VEGF, or by inhibiting the intracellular tyrosine
kinase by small molecules such as sorafenib, sunitinib,
brivanib, linifanib, vatalinib, cediranib, and others. Other
activated angiogenic pathways are Ang2 and FGF signaling.
(2) Epidermal growth factor (EGF) signaling is frequently over-
expressed in HCC [308]. EGFR can be targeted either by
the monoclonal antibody cetuximab or by small molecules
that inhibit the intracellular tyrosine kinase such as erloti-
nib, geﬁtinib, or lapatinib.
(3) Ras MAPK signaling has been shown to be activated in half
of early and almost all advanced HCCs [305,309]. Activa-
tion of this pathway is dependant upon overexpression
of ligands and hypermethylation of promoters of tumor
suppressors inducing transcription of genes of the AP-1
family, such as c-Fos and c-Jun involved in proliferation
and differentiation [310]. Mutations of K-Ras are infre-
quent in HCC (<5%). No selective Ras/ERK/MAPK inhibitor
has been approved, but sorafenib and regorafenib have
shown partial cascade blockage [311].
(4) The PI3K/PTEN/Akt/mTOR pathway. This pathway controls
cell proliferation, cell cycle and apoptosis, and is activated
by various RTKs such as EGFR or IGFR and by inactivation
of the tumor suppressor PTEN. It is activated in 40–50% of
HCCs [312,313]. Several compounds inhibitingmTOR (rapa-
mycin, temsirolimus and everolimus) are tested in phase II
and III studies.
(5) HGF/c-MET pathway. Dysregulation of the c-MET receptor
and its ligandHGF, critical for hepatocyte regeneration after
liver injury, is a common event in HCC [314]. However, their
role in targeted therapy needs further investigation.
(6) Insulin-like growth factor receptor (IGFR) signaling. IGF-1R
and IGF-II expression is increased in HCC, whereas IGFR-
II is downregulated in a subgroup of HCCs [315,316]. Sev-
eral IGF-1R inhibitors are now under early clinical investi-
gation in HCC.
(7) Wnt/ß-Catenin pathway is crucial for hepatocarcinogenesis
[304–306,317–319]. Around one third of HCCs have activa-
tion of the Wnt signaling pathway (particularly HCV-
related HCCs), as a result of activating mutations in the
transcription factor ß-catenin [175,317,318], overexpres-
sion of Frizzled receptors or inactivation of E-cadherin or
members of the degradation complex (GSK3B, AXIN, ade-
nomatosis polyposis coli (APC)) [319]. New compounds
to block this so-called undrugable pathway are under early
clinical investigation.
Additional pathways and their role in targeted therapy such
as the extrinsic/intrinsic apoptotic pathway, Hedgehog signaling,
JAK/STAT signaling, TGF-ß signaling, Notch pathway, ubiquitin–
proteasome pathway, nuclear factor-jB signaling, cell cycle con-
trol, and the role of the tumor microenvironment have to be
further deﬁned. Similarly, the potential role of recently
described oncoMIRs relevant to hepatocarcinogenesis as molec-2 vol. 56 j 908–943 929
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ular targets should be conﬁrmed by clinical investigations
[135,320].
Molecular targeted therapies
Hepatocellular carcinoma is recognized as among the most
chemo-resistant tumor types, and until 2007 no systemic drug
was recommended for patientswith advanced tumors, an unparal-
leled situation in oncology. Sorafenib emerged as the ﬁrst effective
systemic treatment in HCC after 30 years of research, and is cur-
rently the standard-of-care for patients with advanced tumors
[168]. After this study, around56molecular agents are being tested
in phase II and phase III clinical trials [321] (Table 4), the ﬁnal
results of which might lead to updated treatment recommenda-
tions. A summary of the evidence-based data is set out below.
The panel recommends that drug development of novel molecules
inHCC shouldbe basedon the identiﬁcation of oncogenic biomark-
ers to guide a more personalized and stratiﬁed therapy.
Sorafenib
Sorafenib, an oral multi-tyrosine kinase inhibitor, was the ﬁrst
and remains the only drug that has demonstrated survival bene-
ﬁts in patients with advanced HCC. Following an initial phase II
study showing a signal of efﬁcacy [322], a large double-blinded
placebo controlled phase III investigation was conducted, leading
to positive survival results [168]. In this trial, the beneﬁt of
sorafenib was to increase the median overall survival from
7.9 months in the placebo group to 10.7 months in the sorafenib
group (HR = 0.69; 95% CI, 0.55–0.87; p = 0.00058), which repre-
sents a 31% decrease in the relative risk of death. In addition,
sorafenib showed a signiﬁcant beneﬁt in terms of time to pro-
gression (TTP) assessed by independent radiological review with
a median TTP of 5.5 months for sorafenib and 2.8 months for
placebo. The magnitude of survival beneﬁt was similar to that
demonstrated in a parallel phase III trial conducted in theTable 4. Ongoing randomized phase II–III trials aimed to change the standard
of care in HCC management during the period 2012–13.
Indication Randomized studies
Adjuvant 1. Sorafenib vs. placebo
Intermediate HCC 1. Chemoembolization ± sorafenib
2. Chemoembolization ± brivanib
3. Chemoembolization ± everolimus
Advanced HCC
First line 1. Sorafenib ± erlotinib
2. Sorafenib vs. brivanib
3. Sorafenib vs. sunitinib*
4. Sorafenib vs. linifanib**
5. Sorafenib ± Yttrium-90
6. Sorafenib ± doxorubicin
Second line 1. Brivanib vs. placebo**
2. Everolimus vs. placebo
3. Ramucirumab vs. placebo
⁄Halted 2010 for futility/toxicity.
⁄⁄See addendum at the end of the Guidelines.
930 Journal of Hepatology 201Asian-Paciﬁc population, in which hepatitis B was the main cause
of HCC [323]. In this later trial, the median overall survival was
6.5 months in the sorafenib group versus 4.2 months in the pla-
cebo group (HR = 0.68; 95% CI, 0.50–0.93; p = 0.014). The worse
outcome of patients included in this trial, regardless of treatment
allocation, compared with the SHARP investigation, is due to the
fact that the patients had more advanced diseases (ECOG 1–2 or
metastatic disease). From these trials, sorafenib emerged as well
tolerated; the most common grade 3 drug-related adverse events
observed in these studies included diarrhea and hand-foot skin
reaction, which occurred in 8–9%, and 8–16% of patients, respec-
tively. Drug discontinuation due to adverse events was 15% in the
sorafenib arm and 7% in the placebo arm. Drug-related adverse
events were considered manageable, and no death related with
toxicity was described. As a result, sorafenib received the Euro-
pean Medicines Agency (EMEA) authorization in October 2007
and was approved by the USA United Food and Drug Administra-
tion (FDA) in November 2007.
The panel of experts recommends using sorafenib as the stan-
dard systemic therapy for HCC. It is indicated for patients with
well-preserved liver function (Child–Pugh A class) and with
advanced tumors – BCLC C – or those tumors progressing on
loco-regional therapies (concept of treatment migration). No
clear recommendation can be made in Child–Pugh B patients,
although cohort studies have reported a similar safety proﬁle in
patients of this class with no decompensation [324,325]. It is rec-
ommended to maintain sorafenib at least until progression, and
beyond that point second-line studies can be considered. Sorafe-
nib is currently being tested in the adjuvant setting after resec-
tion or complete local ablation for early stages, in combination
with chemoembolization for intermediate stages [326], in combi-
nation with erlotinib or systemic doxorubicin in advanced stages
and as ﬁrst-line treatment in Child–Pugh B patients. Preliminary
data from a randomized phase II study suggest a potential addi-
tive effect in combination with doxorubicin, although a signiﬁ-
cant increase in cardiotoxicity was reported [327].
Other targeted molecules under clinical development
Growth factors and proliferative pathway inhibitors.
mTOR inhibitors. Rapamycin (sirolimus) and its analogs (temsirol-
imus and everolimus) are agents blocking the mTOR signaling
cascade and have been tested in preclinical and early clinical
investigations [328]. Everolimus, an mTOR blocker approved for
kidney cancer therapy, is being tested in phase III for a second-
line indication.
EGFR inhibitors. Five EGFR inhibitors have been tested: erlotinib,
geﬁtinib, cetuximab, lapatinib and vandetanib. Erlotinib showed
activity in a phase II study withmixed HCC populations withmed-
ian survival of 13 months [329], and is currently being tested in
combinationwith sorafenib inphase III. Theotherdrugs eitherhave
not shownmeaningful signals of efﬁcacy in phase II, such as geﬁti-
nib and lapatinib [330], or are still in early stages of investigation.
Anti-angiogenic agents. Sunitinib. Sunitinib is an oralmulti-tyrosine
kinase inhibitor approved for the treatment of renal cell carci-
noma, gastrointestinal stromal tumors and pancreatic neuroendo-
crine tumors. Three reported phase II studies have shown
potential signals of activity, but with conﬂictive adverse events
and treatment-related deaths due to severe liver dysfunction in
5–10% of patients [331–333]. A recent multicenter, open-label
sorafenib-controlled randomized phase III trial was prematurely2 vol. 56 j 908–943
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discontinued for safety issues and futility reasons [334]. This drug
is presently not recommended for treatment of HCC.
Brivanib alaninate. Brivanib, an oral VEGFR and FGFR tyrosine
kinase inhibitor, was evaluated in two phase II studies in ﬁrst and
second-line patients with an advanced tumor. The median overall
survival was 10 months in the ﬁrst-line treated group and
9.8 months in the second-line treated group, with manageable
adverse events [335]. Brivanib is currently tested in three phases
III trials in HCC patients: in ﬁrst-line blinded to sorafenib, in sec-
ond-line blinded to placebo and in combination with
chemoembolization.
Bevacizumab. Bevacizumab, a recombinant, humanized
monoclonal antibody directed against VEGF, has emerged as
an important therapeutic agent in several malignancies and
has been approved in the treatment of colorectal cancer, non-
small-cell lung cancer and breast carcinoma. Bevacizumab has
been evaluated as single agent [336], or in combination with
erlotinib [337] or chemotherapy [338]. As a standalone agent,
it showed objective responses of 10% with median time to pro-
gression of 6.5 months [336]. Combination treatment of bev-
acizumab with EGFR targeting agents reported a median
survival of 15 months for mixed HCC patient populations
[337]. Combinations of bevacizumab with chemotherapy, such
as gemcitabine and oxaliplatin or capecitabine-based regimes,
obtain objective responses of 10–20% with median survivals
of 9–10 months [338]. No phase III investigations with this
agent are ongoing.
Linifanib, an oral tyrosine kinase inhibitor targeting VEGF and
PDGF, and ramucirumab, a monoclonal antibody against VEGFR2
[339] are currently being tested in phase III studies in ﬁrst-line
and second-line indication, respectively. Other new anti-angio-
genic agents, such as vatalanib, axitinib and cediranib are at very
early stages of investigation. Other molecules such as c-MET
inhibitors, MEK inhibitors, TGF-beta and JAK2 inhibitors are being
tested in early clinical investigations [321].
Other systemic therapies
Several systemic therapies, including chemotherapy, hormonal
compounds, immunotherapy and others showed inconclusive or
negative results. These agents are not currently recommended
for management of HCC.
Chemotherapy
The problem of using chemotherapy in HCC stems from the co-
existence of two diseases. Cirrhosis can perturb the metabolism
of chemotherapeutic drugs and enhance their toxicity. In
addition, some chemotherapy-related complications, such as
systemic infections, are particularly severe in inmmunocompro-
mised patients, like cirrhotics. On the other hand, HCC has been
shown to be chemoresistant to the most common chemothera-
pies, which as single agents have reported modest anti-tumoral
response [139,340–342]. Systemic doxorubicin has been evalu-
ated in more than 1000 patients in clinical trials with an objec-
tive response rate of around 10%. In a 446-patient trial,
nolatrexed, an inhibitor of thymidylate synthase, was compared
to systemic doxorubicin with negative results (median survival
5 months versus 7.5 months, respectively) and response rates
for the doxorubicin arm of 4%. Other systemic therapies suchJournal of Hepatology 201as gemcitabine, oxaliplatin, cisplatin and capecitabine used as
single agents or in combinations have reported heterogeneous
responses ranging from 0% to 18% in uncontrolled investigations
[340].
Systemic chemotherapy using combinations of two or
more agents has been tested in recent RCT. A large RCT
which compared combination chemotherapy (Cisplatin/Inter-
feron a2b/Doxorubicin/Fluorouracil-PIAF regime) versus doxo-
rubicin chemotherapy showed objective response rates of
20.9% and 10.5%, respectively [342]. The median survival of
the PIAF and doxorubicin groups was 8.67 months and
6.83 months, respectively, without differences between
groups. PIAF was associated with a signiﬁcantly higher rate
of myelotoxicity compared with doxorubicin. Treatment-
related mortality was 9% in the PIAF regimen arm as a
result of HBV reactivation and liver failure. A second RCT
conducted in Asia compared the efﬁcacy of the Folfox regi-
men combining 5-ﬂuorouracil, folinic acid and oxaliplatin
against doxorubicin alone. This study included 371 patients
with Child–Pugh A/B advanced non-operable or metastatic
HCC (BCLC B/C). There was a non-signiﬁcant trend favoring
the Folfox group (median survival 6.4 mo versus 4.9 mo;
p = 0.07) associated to a better time to progression (2.9 mo
versus 1.7 mo) [343]. Chemotherapy for HCC in non-cirrhotic
patients is an underexplored area [344]. Thus, considering
the available evidence, systemic chemotherapy is not recom-
mended for the treatment of HCC, nor as a control regime
for any trial due to the well-known toxic effects. Phase III
investigations combining chemotherapy and sorafenib are
ongoing.
Hormonal compounds
Hormonal compounds have not shown survival beneﬁts in
HCC. A meta-analysis of seven RCT comparing tamoxifen
versus conservative management, comprising 898 patients,
showed neither anti-tumoral effects nor survival beneﬁts
for tamoxifen [139]. Two large RCT were reported after-
wards assessing tamoxifen [345,346] with negative results
in terms of survival. Thus, this treatment is discouraged in
advanced HCC. Antiandrogen therapy is not recommended
[347].
Immunotherapy
HCC is a typical inﬂammation associated cancer. A number of
different studies have demonstrated a correlation between
immune responses to tumors and patient outcome [348].
Immune-based therapy phase I–II trials have been performed
at centers with the appropriate expertise but results have not
been conﬁrmed by independent investigators [349]. The concept
of immunotherapy requires further investigations from phase II
and III studies.
Other treatments
A large RCT compared seocalcitol – a vitamin D like antiprolifera-
tive molecule – versus placebo in 746 patients and showed no dif-
ferences in overall survival (9.6 months seocalcitol versus
9.2 months placebo) [350]. Finally, negative results were also
reported with a tubulin inhibitor (T-67) in a large multicenter
RCT [351].2 vol. 56 j 908–943 931
Clinical Practice Guidelines
Trial design
1. The panel endorses the trial design and selection of end-
points for clinical trials in HCC proposed in previous JNCI 
guidelines (Fig. 5) and lists the high-end trials currently 
ongoing which, in case of demonstrating 
clinically relevant superiority vs. the standard of care, 
might change the current guidelines (Table 4) 
2. Assessment of response: 
• Assessment of response in HCC should be 
(mRECIST; Table 5)
(recommendation 2B)
Use of changes in serum levels of biomarkers for 
assessment of response (i.e. AFP levels) is under 
investigation
• Dynamic CT or MRI are recommended tools to 
assess response one month after resection, loco- 
regional or systemic therapies 
(recommendation 1A)  
Follow-up strategies for detection of recurrence 
include one imaging technique every 3 months 
to complete at least two years. Afterwards, regular 
ultrasound is recommended every 6 months.
Assessment of time to progression is recommended 
with CT and/or MRI every 6-8 weeks
based on the modification of the RECIST criteria
during the first year, and every six months thereafter
The increasing number of ongoing clinical trials in HCC has
created the need for a common frame to test novel drugs
accepted by all disciplines. As a consequence, new guidelines
on the design of clinical trials and end-points in HCC have been
reported by a multidisciplinary panel of experts [149]. TheseBCLC 0-A
(early HCC) (in
Resection, transplantation,
percutaneous ablation
Adjuvant
Plabebo vs. drug
P
Ch
TAC
TAC
Standard of care
First line
Second line
Fig. 5. Summary of trial design strategies and control groups. Adapted from Llovet e
932 Journal of Hepatology 201statements will evolve as new evidence becomes available,
including more precise information on the natural history of
HCC, new drugs or predictive biomarkers. The panel endorses
the trial design and selection of end-points for clinical trials in
HCC proposed in previous Journal National Cancer Institute
guidelines [149]. In addition, the panel wants to emphasize that
the integrity of research is absolutely vital for the advancement
of evidence-based medicine. If a study proposing a major change
in clinical practice is accepted yet its ﬁndings are fraudulent, as
recently occurred in HCC with a study that required retraction
[352], the threat to patient safety and management could be
enormous.
The main recommendations for trial design are summarized
below:
(1) End-points. Survival and time to recurrence were pro-
posed as primary end-points for phase III studies assess-
ing primary and adjuvant therapies, respectively.
Composite end-points such as disease free survival
(DFS) or progression free survival (PFS) are suboptimal
in HCC research, and should be included as secondary
end-points. Randomized phase II studies were consid-
ered pivotal prior to conducting phase III trials in HCC.
These studies classically consider response rate as the
gold-standard for efﬁcacy, but time to progression was
recommended as the primary end-point when testing
molecular targeted therapies [149]. The panel considers
that further data is needed to establish response rate
as per mRECIST as surrogate of survival. Quality of life
assessment in HCC research suffers from the lack of a
reliable, standardized and adequately validated question-
naire, and thus, it is currently recommended as ancillary
information.
(2) Trial design is summarized in Fig. 5. Selection of patients
should be based on BCLC staging and Child–Pugh A class,
in order to minimize the competitive risk of death
associated with liver failure. The control arm for clinicalBCLC B
termediate HCC)
BCLC C
(advanced HCC)
Plabebo vs .
vs.
vs.
vs.
vs.
drug
Sorafenib +
drug
drug
rimary treatment Primary treatment
emoembolization-
TACE
E
E
TACE +
drug/device
Drug/device
Sorafenib
Sorafenib
Sorafenib
In case phase II findings were very promising
t al. [164].
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Table 5. Assessment of response comparing RECIST and mRECIST.⁄
Target lesions
Response category RECIST mRECIST
CR Disappearance of all target lesions Disappearance of any intratumoral arterial enhancement 
in all target lesions
PR At least a 30% decrease in the sum of the diameters of 
target lesions, taking as reference the baseline sum of 
the diameters of target lesions
At least a 30% decrease in the sum of the diameters 
of viable (enhancement in the arterial phase) target 
lesions, taking as reference the baseline sum of the 
diameters of target lesions
SD Any cases that do not qualify for either PR or PD Any cases that do not qualify for either PR or PD
PD An increase of at least 20% in the sum of the diameters 
of target lesions, taking as reference the smallest sum of 
the diameters of target lesions recorded since treatment 
started
An increase of at least 20% in the sum of the diameters 
of viable (enhancing) target lesions, taking as reference 
the smallest sum of the diameters of viable (enhancing) 
target lesions recorded since treatment started
Non-target lesions
Response category RECIST mRECIST
CR Disappearance of all non-target lesions Disappearance of any intratumoral arterial enhancement 
in all non-target lesions
IR/SD Persistence of one or more non-target lesions Persistence of intratumoral arterial enhancement in one 
or more non-target lesions
PD Appearance of one or more new lesions and/or 
unequivocal progression of existing non-target lesions 
Appearance of one or more new lesions and/or 
unequivocal progression of existing non-target lesions 
mRECIST recommendations
Pleural effusion and 
ascites required to declare PD.
Porta hepatis lymph 
node
Lymph nodes detected at the porta hepatis can be considered malignant if the lymph node short axis is at least 2 
cm.
Portal vein 
thrombosis
Malignant portal vein thrombosis should be considered as a non-measurable lesion and thus included in the non-
target lesion group.
New lesion
typical for HCC. A lesion with atypical radiological pattern can be diagnosed as HCC by evidence of at least 1 cm 
interval growth.
Cytopathologic confirmation of the neoplastic nature of any effusion that appears or worsens during treatment is
A new lesion can be classified as HCC if its longest diameter is at least 1 cm and the enhancement pattern is
RECIST, Response Evaluation Criteria In Solid Tumors; mRECIST, modiﬁed Response Evaluation Criteria In Solid Tumors; CR, complete response; PR, partial response; IR,
incomplete response; SD, stable disease; PD, progressive disease.
⁄Adapted from Llovet et al. [149] and Lencioni and Llovet [100].
JOURNAL OF HEPATOLOGYtrials should be the standard of care, meaning chemo-
embolization for intermediate HCCs and sorafenib for
advanced cases. Therefore, for the assessment of ﬁrst-
line systemic treatments for advanced HCC a design add-
ing a new agent to sorafenib versus sorafenib alone is
recommended. Comparison of single agents head-to-
head with the standard of care therapy might jeopardize
the recruitment of patients for ethical reasons, unless
the novel agent showed very promising efﬁcacy in early
phase II studies. For second-line treatments, the new
agent should be randomized against placebo/best sup-
portive care, and the selection criteria should include
patients with contraindications or failures to sorafenib.
Randomized studies testing molecular targeted therapies
should optimally include biomarker analysis (tissue and/
or serum samples) to enable the identiﬁcation of molec-
ular markers of response and for pharmacokinetic pur-
poses, as reported in other cancers.Journal of Hepatology 201(3) Assessment of tumor response. The main end-point in can-
cer research is overall survival. Nonetheless, tumor
response and time to progression have been considered
pivotal for surrogate assessment of efﬁcacy. In oncology,
tumor response was initially measured according to the
World Health Organization (WHO) criteria [353], and
afterwards according to the Response Evaluation Criteria
In Solid Tumors (RECIST) guidelines [354,355]. These
criteria were designed primarily for evaluation of cyto-
toxic agents. They do not address measures of antitumor
activity other than tumor shrinkage. As acknowledged in
the original RECIST publication, assessments based solely
on changes in tumor size can be misleading when
applied to other anticancer drugs, such as molecular
targeted therapies, or other therapeutic interventions
[354]. EASL and AASLD guidelines adopted a modiﬁed
version of a WHO criterion in which the evaluation of
the treatment response accounted for the induction of2 vol. 56 j 908–943 933
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intra-tumoral necrotic areas in estimating the decrease
in tumor load, and not just a reduction in overall tumor
size [1,56].Table 6
1. Cl
3. Pr
5. Se
2. Ide
4. Sy
934Results from a number of previous clinical studies in HCC
have demonstrated that RECIST criteria do not mirror the
extent of tumor necrosis induced by interventional thera-
pies or new molecular targeting drugs [168,356]. Viable
tumor formation needs to be assessed using CT or MRI
studies and viable tumor should be deﬁned as uptake of
contrast agent in the arterial phase of dynamic imaging
studies. Consequently, a modiﬁcation of the RECIST crite-
ria was ﬁrst proposed by a panel of experts [149], and
further expanded [100]. This proposal is based on the fact
that diameter of the target lesions with viable tumor
should guide all measurements. In addition, speciﬁc mod-
iﬁcations of the original criteria regarding assessment of
vascular invasion, lymph nodes, ascites, pleural effusion
and news lesions have been summarized in Table 5.
Objective response rates using mRECIST have been
reported of 57% in patients treated with chemoemboliza-
tion [357], 90Y [358], 20% with sorafenib [359,360] and
15–25% using brivanib [335]. The panel of experts recom-
mends to assess tumor response according to mRECIST
criteria, and to test whether these criteria have better
performance than conventional RECIST, and correlate
with pathological studies and outcome prediction
(Table 6).. Unmet needs in HCC research.
inical development of drugs
Targeting pathways with few candidates in the pipeline 
such as Wnt/β-catenin, Hedgehog/Gli, Notch and ERK 
pathway
Improve models for pre-clinical testing of novel drugs
Prognostic biomarkers: independent validation of prognosis 
at all stages of the disease from serum (AFP, Ang2, VEGF) 
and tissue (gene signatures EpCAM, G3-proliferation, poor 
survival signature; miR26)
targeted therapies
Surrogates of microvascular invasion
operly designed and powered clinical trials for:
• Adjuvant therapy after curative treatments
• Therapies to prevent drop-outs in the waiting list and 
downstaging strategies
• Combinations of local with systemic therapies
• Combinations of systemic targeted therapies
• Second-line therapies
• Radioembolization
arch for tools to assess quality of life in clinical trials
ntification and validation of biomarkers
Predictive biomarkers: response to specific systemic
stematic inclusion of cost-benefit analyses in clinical trials
Journal of Hepatology 201Final considerations
1. The panel considers that collection of tissue and serum 
samples in research studies is highly desirable and 
recommended. Such biobanking should permit  the 
achievement of two clinical goals:  
• 
staging system. Molecular data such as gene 
signatures (poor survival, EpCAM) or biomarkers 
(AFP, VEGF, Ang2 and miR26) have been shown to 
likely to be incorporated into staging systems after 
external independent validation
• 
medicine. Molecular therapies blocking 
angiogenesis (VEGF, PDGF, Ang2, FGF) or 
proliferation cascades disrupted in HCC (EGFR, 
Ras, Akt, mTOR, IGF-1R, MET) are tested in 
advanced clinical trials. Discovery of biomarkers can 
of treatment responders, and, therefore, constitutes 
a major short term goal
2. The panel has listed and categorized here the main 
rized manner (see Table 6). It is strongly recommended 
that physicians, investigators, health policy agencies, 
pharmaceutical industry and care providers devote future 
resources as a priority to: 
• Evaluating adjuvant therapies after resection/local 
ablation
• Exploring downstaging strategies to rescue patients 
with HCCs beyond conventional Milan criteria
• 
therapies with local ablation and loco-regional 
treatments
• Building the backbone package treatment for 
advanced tumors and second-line therapies
• 
studies with collection of health economic analysis 
such as incremental cost effectiveness ratio in order 
to facilitate clinical decision-making
• Providing adequate quality of life assessment tools. 
The panel considers quality of life as a relevant 
of instruments for such assessment in HCC patients 
is needed
3. 
surveillance and treatment strategies are available in 
HCC, the proportions of patients receiving these 
interventions are suboptimal [47]. Measures to increase 
access to surveillance, early diagnosis and effective 
treatment should be implemented in order to increase the 
effectiveness
Refinement of prognostication and BCLC
have independent prognostic significance and are
Moving towards personalized/stratified
be instrumental for trial enrichment and identification
unmet needs in the field of HCC research in a catego-
Evaluating the benefits of combining molecular
Including cost-benefit approaches in research
end-point for research studies, and thus, refinement
Translating efficacy into effectiveness: Despite effective2 vol. 56 j 908–943
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Addendum
During the editing process of the guidelines additional informa-
tion on two phase 3 RCT mentioned in Table 4 was reported.
1. The study comparing brivanib vs. placebo in patients with
advanced HCC failing or intolerant to sorafenib was reported
not meeting the primary end-point survival. http://www.busi-
nesswire.com/portal/site/home/email/alert (Jan 2012).
2. The study comparing linifanib vs. sorafenib in ﬁrst-line was
halted by the DSMC at the interim analysis. Abbott’s LiGHT
(Linifanib Study M10-963) Early Study Closure).Disclosures
These guidelines reﬂect the state of knowledge, current at the
time of publication, on effective and appropriate care, as well
as clinical consensus judgments when knowledge is lacking.
The inevitable changes in the state of scientiﬁc information and
technology mandate that periodic review, updating, and revisions
will be needed. These guidelines do not apply to all patients, and
each must be adapted and tailored to each individual patient.
Proper use, adaptation modiﬁcations or decisions to disregard
these or other guidelines, in whole or in part, are entirely
the responsibility of the clinician who uses the guidelines. The
content of this publication does not necessarily reﬂect the
views or policies of the Department of Health and Human
Services, nor does mention of trade names, commercial products,
organizations or imply endorsement by any European or USA
Government.
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